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Ab t ract  
I n  ear l ier studi s, cannabidiol (CBD), a major n np chotropic cannabinoid found 
in cannabi plant, ha b n shown to in fluence cardiovascular function under anous 
phy iol gical and pathological conditions. In the pre ent study. the effects of BD on 
contracti l i ty and electrical prop rt ies of rat ventricular myocytes were investigated. V ideo 
edge detection \ a u ed to measure myocyte shorteni ng. Intracel l ular Ca2+ was measured 
in cel l loaded with the fl uore cent indicator fura-2 AM.  CBD ( 1  jJ.M) caused a 
igni ficant d crease in the ampl itudes of e lectrical ly-evoked myocyte shortening and Ca2+ 
tran ient . However, the an1p l i tudes of caffeine-evoked Ca2+ transients and the rate of 
re over of electrical ly-e oked Ca2+ transients following caffeine appl ication were not 
al tered. Whole-ce l l  patch-clamp tecJmique was employed to invest igate the effect of CBD 
on the characterist ics of action potentials CAPs) and L-type Ca2+ channels .  CBD (1 �LM) 
significant ly  decreased the duration of A Ps .  Further studies on L -type Ca2+ channels  
i ndicated that CBD i nh ibits these channels wi th IC50 of 0 . 1 jJ.M i n  a voltage-independent 
manner. 
Keywords: Cannabidiol, I type calc ium channels, ventricular myocyte. 
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C h a pter  1: In t rod u ct ion 
1.1 Aim and Object ive : 
The aims of thi re earch are to examine the th rap utic potential and mechanism b 
\ \hich the ph) tocannabinoid annabidiol  CBD affect card iac contracti l ity. Thi s will be achieved 
by i l1\ e tigating the effects of CBD on action potential duration, ventricular shortening, 
my ofilament ensitiv ity, and L-type calcium current. 
1.2 Hi tory 
larij uana i a c rude preparation of flowering tops, lea es, seeds and stems from female 
I ndian hemp cannabi sati a plants ( F igure 1). It has been used for centuries for both recreational 
and therap utic purposes .  CUITently cannabis is  bei ng in  estigated for the treatment of various 
pathological conditions uch as pain, nausea, vomiting and cancer. I t  is  one of the most 
exten ively studied p lants. There were more than 12,000 PubMed artic les publ ished in January 
2014 u ing the key word cannabis i n  relation to the various biological and phannacological 
effects of thi drug. 
Figu re 1 .  Can nabis Sat iya Leaves.ScienceDai ly, n.d. Web. 30 Apr. 2014 
.0.CI-Tetrahyorocannabtnol ( 
OH 
Cannablchromene (CSC) 
Figu re 2. Majo r Phytoca n nabi noids 
OH 
Cannabinol (CBN) 
� 
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The medicinal u e of marijuana has a long history of th rapeutic u e, going back 
several thousand of ears. It \ as often used for the sanle medical cond it ions it is used to 
treat toda uch a mu c le  spa m , pain, nausea, omit ing, epi lepsy, and glaucoma. 
Howe er, use of marijuana is  also a sociated with distorted percept ion (sights, sounds, 
time and t uch), panic attack , trouble with thinking, d i fficul t ies in learning and problem 
olving, and 10 of motor coord ination. Due to these adverse effects, the use of 
marijuana was banned in the U .  and throughout most o f  the world almost eighty years 
ago. 
During the second half  of the 20th century, researchers disco ered that the 
biological actions of marijuana are mediated mainly by a group of chemicals col lectively 
cal led cannabinoids. A lthough cannabis p lant extracts contain more than 460 compounds 
based on pharmacological properties and radiol igand binding studies, current ly  about 
6 0  of the compound found in this p lant, are col l ectively named phytocannabinoids. 
Among these phytocannabinoids, "....9 -Tetrahydrocannabinol (THe) i s  a major chemical 
that mediates the psychoact ive actions of the cannabis p lant ( Figure 2). In  addition to 
THC, other cannabinoids such as Cannabigerol Cannabichromene, Cannabinol (CBN) 
and Cannabidiol (CBD), constitute major non-psychoact ive components of the cannabis 
p lant .  These compounds are h ighly l ipophi l ic and bear signi ficant s imi larities in their 
chemical  structure. For example, CBD which is  the focus of this study, is  a structural 
i somer of THC i .e .  it has the same chemical composit ion but the atoms are arranged 
d ifferentl y .  
Whi le the majority of the adverse psychological effects of marij uana are known to 
b med iated by TH , the contribution of other cannabinoids such as CBD and CB to 
the 0\ crall in fl uence of marij uana remains unknown . In recent years, various 
combinat ions of th c psychoacti e and non-p ychoacti e cannabinoids ha e been used 
in annabi based treatments. Di fferent extract of cannabis have been used 
therapeutical l y  to re l ie e, a thma, pain whooping cough, epi lepsy and inflammation. 
Ho\,\ ,evcr, due to the p ychoa t i  e effects of  cannabis such as anxiety, cognit ive 
impaim1ent and hal luc inations, medici nal use of these compounds was d iscontinued 
( Robson, 200 1 ). 
evetthel ess, i ts therapeutic potential to solve a myriad of medical problems has 
attracted con iderable  re earch interest.  Thus, in recent years research has focused on 
the therapeutic potential of the plant to develop new chemicals that retain the therapeutic 
benefits wi.thout causing psychotropic  effects. 
© Joachim SchroCer 
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1 .3 a n n a b i n oid 
De pit its u e [or centuries, the act ive ingredient and chemical con ti tuents 
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Of the cannabi plant remained largely unknovv n unt i l  the begi lUling of the 1 960s when 
th mai n p ychoactive consti tuent. THC \Va e tracted and identified ( Mechoulam & 
aoni ,  1 965) .  l n  the 1 980s, other compounds \ i th chemical structures simi lar to that of 
TIlC \Y re ynthesized b various drug companies in  an attempt to discover new drugs to 
al leviate pain .  ome o[ these newly synthesized compounds such as CP55,940, 
P5�,244, H -2 1 0, JWH-0 1 8  di placed rad ioacti  e ly labeled THC in  radiol igand 
binding experiments and lead to th disco ery of the first cannabinoid receptor 
( B 1 )  in  the brain ( Herkenham et a l . ,  1 990) .  I n  the 1 990's CB 1 and CB2 receptors 
were c loned. expressed functional ly and identi fied pharmacological ly  ( Pertwee, 1 997) .  
Further studie in  this field.  i ndicated that, s imi lar to opioids, there are 
endogenous l igands that can bind and activate cannabinoid receptors. These findings 
eventua l ly  lead to the d iscovery of "endocannabinoids" i .e .  endogenously produced 
cannabi noids.  E ndocannabinoids mainly -arachidonoylethanolamine ( Anandamide; 
AEA) and 2-arachidonylglycerol (2-AG) have considerable  agonistic effects on the 
cannabinoid receptors ( M echoulam et a1 . .  1 995) ,  and mimic most of the pharmacological 
actions of THC. 
1 .3.1 Ph) toca n n a b i n o i d  
s mentioned earl ier the most abundant const i tuents of  the cannabis plant are 
TI lC and BD. Within the plant ,  ph tocannabinoids are synthesized from fatty acid 
precur r , in a series of trans[eras and synthase enz mes (Figure 3 ) . The two major 
ph;t annabinoids. THC and CBD, are derived from a common synthet ic precursor, 
cmmabigero l .  From a phmmaco-chemical perspect ive. whi l st THC and CBD ha e pentyl 
side chain . major homologues are 69-tetrahydrocannabi arinand cannabidivarin, 
respect i\  e l ) . with prop I ide chains, derived from cannabigerovarin.  Importantly, 
de pite only smal l  d i fference in chemical structme, these compounds appear to exhibit 
marked l )  d ifferent pham1acoiogical propert ies ( H i l l .  W i l l imns. Whal ley, & Stephens. 
20 1 2) .  
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THC has a wide spectrum of pharmacological effects ranging from anti­
i ntlanm1atory and analgesic actions to cancer treatment, mainly through the act ivation of 
the cannabinoid receptors (Mechoulam, Parker, & Gal l i l y  2002). Howe er, CBD has no 
agonistic act iv i ty on cannabinoid receptors, but i t  i s  capable of producing various 
pharmacological effects by acting on d iverse groups of target proteins ranging from 
enzymes and receptors to neurotransmi tter transporters and ion chan nels ( H i l l  et al., 
20 1 2). 
1.3.2 E n doca n n a b i noid  
Endogenou l igand for the cannabinoid receptor are synthesized from 
p Iyun aturated fatty ac id and fatt ac id deri atives from glycerol . They mimic  the 
actions of phytocannabinoid by binding to cannabinoid receptors ( Di Marzo, 2008) .  In 
addit ion to E and 2- G. other endocarmabinoid with s imi lar fatty acid-based 
chemical tructures have also been ident ified in  the last decade ( Pertwee et a I . ,  20 1 0 ). 
orne of the e endocannabinoids incl ude 2-arach idonylglycerol ether (Noladin ether); 
( H anus et a I . ,  200 1 ). DA. and virodhamine ( Pertwee et aL 20 1 0; Porter et a I . ,  2002 ) .  
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Endocannabinoids, unl ike neurotransmi tters, are neither synthesized nor stored i n  
the neurons. Therefore they are not released b y  a synapt ic process, but produced in  
re ponse to  cel lu lar act iv i ty (Di  Marzo et  a1 . ,  1 994 ) .  I t  has been shown that biological 
proce se such as membrane depolarization and act ivat ion of metabotropic receptors 
cause i ncreases in i ntrace l l ular Ca2 levels  and act ivate enzymes i nvolved in the synthesis 
of  endocannabinoids ( Di Marzo. 2008). Fol lowing their synthesis, AEA and 2-AG are 
degraded by enzymatic hydrolysis by fatty ac id amide hydrolase ( FAAH) and 
monoacylglycerol l ipase ( MAGL). respectively ( Cravatt & L ichtman, 2002) .  
E ndocannabinoids can also be transported out of the cel l by d i ffusion through cel l 
membranes or by a mechanism that involves an unidentified transporting protei n  located 
in the p lasma membrane (Cravatt & Lichtman. 2002 ; Glaser, Kaczocha, and Deutsch, 
2005). 
1 .3.3 y n t h et ic  C a n n a b i n o i d  
Fol lowing the di  co very of  cannabinoid receptors there have been attempts to 
produce ompound with therapeutic effect uch as anti - in flammatory/analgesic and 
anti-emetic effects without inducing the psychotropic effects. As a re ul t  various 
chemicals such as CP55 ,940, CP5 5,244,HU-2 1 0, JWH-O 1 8 , and J WH-073 have been 
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nthesized ( I Iuffman et aI . ,  1 998) .  These compounds are known col lect ively as synthet ic 
cannabi noid (A hton, 2 0 1 2) .  Currently,  l i tt le is  known about the biological act ivit ies of 
the e compounds with their diverse chemical structures. However, recent reports i ndicate 
that various combination of synthetic cannabinoids are employed for recreat ional 
purpo e throughout the world in  order to a oid legal regulations related to 
phytocaIUlabinoids ( B urste in and Zur ier, 2009). However, the synthetic cannabinoid 
abi lone has recently been approved by the FDA ( U . S  Food and Drug Administrat ion) 
and recommended for the treatment of chemotherapy- induced nausea and vomit ing that is  
unre ponsive to conventional antiemetics ( Ware, Daeninck, and Maida 2008) .1n addition 
nabi lone is  used for the treatment of anorexia and weight loss in A I DS patients ( B urste in 
and Zurier, 2009: Pertwee et  a I . ,  2 0 1 0) .  Nabilone has a lso been reported to be an effective 
pain k i l ler for patients with fibromyalgia ( Skrabek Gal imova, Ethans, & Perry, 2008) .  
C urrently the fol lowing cannabinoid based medications have been approved by 
the FDA and are commercia l ly  avai lable ( Schicho & Storr, 20 1 1 ) : 1 - Sativex® (GW 
Pharmaceuticals), for pain and spastic i ty i n  pat ients wi th  mult iple sc lerosis .  Currently, 
four d ifferent formulat ions of Sativex® are under i nvestigation, including the h igh 
THC extract (Tetranabinex®), THC:CB D  (narrow rat io), THC:CB D  (broad ratio) 
and the high CBD extract (Nabidiolex®) ( Scuderi et a1 .  2009) .  currently, three 
,'at i \  ex R del ivery s tern exi st: the oromucosal spray, subl ingual tablets and inhaled 
dosage form . In 2005, the oromuco al spray administrat ion of ativex was approved 
[or the treatment of mult iple sc lerosis ymptoms ( Perras 2005 ). To date, ativex 
preparat ion ha e been l icen ed in Canada, the UK and Spain. 2- Marinol ( olvay 
Pharmaceuticals, Belgium), oral capsules containing dronabinol (a synthetic THC),  are 
recommended as an appetite stimulant and antiemetic .  3- Cesamet (Valeant 
Pha1111aceuticals I ntemational ) ,  is an oral capsule containing nabiione (a synthet ic THC 
analog), for patients \',:ith chemotherapy-induced nausea and vomit ing. Til is  drug is  
cUITently l icen ed in  Canada, the U A and the UK. 
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Table 1 .  Cia of Cannabinoid 
Major CIa arne 
Phytocannabinoid 9 Tetrahydrocannabinol (�9 THC) 
Cannabigerol (CBG) 
Cannabidiol  (CBD ) 
Cannabichromene (CBC) 
Cannab inol (CBN ) 
Endocannabinoids 2-Arach idonylethanol Amide 
( Anandamide)  
2-Arach idonylglycerol (2-AG) 
O-Arach idonylethanolam ine 
( Yirodami ne)  
I I  
Action ofCB 
Receptor 
Non se lective CB l /CB2 
agonist 
CB I selective 
antagonist 
CB I antagon ist 
CB2 inverse agonist 
No action on CBR 
Non selective CB I IC B2 
agonist 
Non se lect ive CB l ICB2 
agonist 
Non select ive CB 1 /CB2 
agonist 
Non selective CB l ICB2 
agon ist 
1 2  
Synthetic C P55 ,940 Non selective CB l ICB2 
Cannabinoid agoni  t 
WfN 55,2 1 2  Non se lect ive C B  l /CB2 
agon ist 
Sch .336 CB2 se lective 
Aju lemic ac id (AJA)  Non se lect ive C B l /CB2 
agonist 
1 .4 a n n a b idio l  
'ED i the main n n-p choactive c mponent of cannabis and onst itutes up to 
400 0 r cannabi extract (Grlic, 1 962) .  I t  was first i solated in  1 940 and its chemical 
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truct llre \va identi fied i n  1 963 ( Mecholliam and Hanus, 2002).  I n  recent ears, CBD has 
been con idered t be a promising therapeutic agent for c l in ical use, since, in addit ion to 
it non-p'ychotropi properti ,it exhibits a wel l  as low tox ic ity in humans and has a 
high therapeut ic index and a low t ratogenic potential ( Ro enkrantz, Fleischman ,  and 
rant, 1 98 1 ;  ampos, oreira, Gomes, Del Bel, and Guimaraes, 20 1 2 ; cuderi et a1. ,  
2009). n oral ly-admini  tered l iquid containing CBD has received orphan drug status in 
the . for u e as a treatment for Dravet Syndrome, a rare-foml of epilepsy that i s  
rc  istant to  treatment with current ant i -epi lept ic drug (Gloss, Nolan ,  and Staba, 20 1 4) .  
Cannabidiol  i s  insoluble in water but soluble i n  organic sol  ents, such as DMSO 
and alcoho l .  I t  i rapid ly  distributed when administered intravenously, easi ly passes the 
blood-brain barrier and has a prolonged e l imination from the body (Samara Bialer and 
Harvey, 1 990).  
1.-'-1 Mec h a n is m s  o f  Action of C a n n a b i d iol 
I n  general ,  C B D  has been shown to act on a wide range of molecular and cel lu lar 
target sites. Some of these molecular targets are various types of membrane receptors 
such as GPR55 ( Ryberg et a I . ,  2007), opioid ( Kathmann, Flau, Redmer, Trank le  and 
chl icker, 2006) and 5 HT 1 A  receptors as wel l  as Transient Vanni lo id  receptors 1 
(TRPVl) (B i sogno et a1. ,  200 1 ), and Peroxisome Prol i ferator Activated Receptor 
(PPARy) (B i shop-Bai ley, 2000). Signi ficant ly  CBD, at low 11M concentrations acts as an 
antagonist for CB 1 and C B2 receptors ( Pertwee, Ross, Craib and Thomas, 2002). Other 
1 4  
protein that BO interact with incl ude v l tage-gated and l igand-gated ion channe ls. and 
various type of enzy me ( for review ee Pertwee, 2008;  Izzo et a1. .  2009: Campos et aI., 
2 0 1 2 :Gar ia-Arencibia et aL 2007). The e cel lular and molecular target are di scussed in 
d tai l in  the fo l lo\-ving ections. 
a .  Act ion  of ca n n a b id io l  on the ca n n a b i n o i d  y tern: 
In earl ier C\ in i  al tudie , CBO,  " ith no detectable act ivi ty by i tse l f, was reported 
to attenuate orne of the effects ofTHC such as anxiety and tachycardia ( Kamiol ,  
h iraka\\ a, Ka in  k i ,  Pfeferman and Carl in i ,  1 974 . S imi larly, it was found that the 
phaJmacological act ions of cannabinoid receptor agonists can be antagonized by 10\ (nM 
range) c ncentrat ion of CBD in  a mouse's va deferens ( Pertwee et a I . ,  2002) .  These 
effects of CBD are unl ikely to involve d irect interaction at canl1abinoid receptor CB 1 and 
C B2 binding sites except at high concentrations of CBD,  since CBD appears to have a 
relatively low affinity for cannabinoid receptors. Ki values for CBD-induced 
displacement of a radiolabe l led l igand from cannabinoid CB 1 and C B2 receptor binding 
s i tes ha e been reported to be 4 .35  and 2 . 86 fJ.M, respectively in one study ( Showalter, 
Compton, Mart i n  and Abood, 1 996) and > 1 0 fJ.M in other experiments ( Devane, Dysarz, 
Johnson, Melvin and Howlett, 1 988; Bisogno et a I . ,  200 1 ) . Further studies indicated that 
CBD behaves as a h igh-potency antagonist for cannabinoid receptor agonists in a 
mouse's bra in  t issue and i n  membranes from CHO cel l s  transfected with cal1nabinoid 
receptors (Thomas et a1.  2007) .  It  was also reported that the function of a novel receptor 
GPR55 is inhibited by low concentrations of CBD ( Ryberg et a ! . ,  2007). 
1 5  
Th interaction of CBD with the cannabinoid system is not l imi ted to cannabinoid 
recept r . Ti sue levels of endogenously produced cannabin ids are also affected by 
BD.  For ample, it ha be n sho\ n that CBD i nh ibits the uptake and the enzymatic 
hydrolysi of AE (B i sogno et a I . ,  200 1 ). Furthermore, CBD ha been shown to cause 
activation of cannabinoid receptors indirect ly  by enhancing t issue concentrations of 
endocannabinoids ( Fowler, �004) .  In funct ional e periments it has been suggested that 
orne of the effect of CBD sensit ive to CB receptor antagonists are mediated by an 
entourage effect of CBD on t issue levels of endocmmabinoids ( Fowler, 2004) .  
b .  Effects o f  ca n n a bid iol  o n  oth er mem b ra n e  recepto rs: 
CBD has been shown to stimulate Van i l loid Receptors (V R l )  with an efficacy 
comparable to that of capsaicin,  the natural agonist of this receptor ( B isogno et aI . ,  
200 1 ) . The st imulation o f  the V R I receptor b y  capsaicin and some o f  i t s  analogues leads 
to fa t desensi tization, with subsequent analgesic and ant i - infl ammatory effects. It has 
been suggested that, s imi lar to capsaicin,  CBD also causes desensit ization of VR l and 
enhances the effect of capsaic i n  on V R l , suggesting that C B D  exerts its anti ­
inflammatory actions, in  part, by desensitization of sensory noc iceptors (B i sogno et  a I . ,  
200 1 ) .CBD has been reported to  act as a weak agonist ( ECso = 3 .5  )lM) on human 
TRPV 1 receptors i n HEK293 ce l ls  expressing these receptors ( De Petrocel l i s  et a1. ,  20 1 1 ) . 
CBD has al so been demonstrated to act as an agonist on TRPV2 (Qin et a I . ,  2008) and 
TRP Al receptors, whi le  it acts as an antagonist on the TRP M 8  receptor ( De Petrocel l is et 
a1. , 2008) .  
I t  was also shown that a t  a )lM concentration range, CBD displaces the 8-0H­
D PAT 5-HT I A  receptor agonist ,  from cloned human 5-HT I A  receptors expressed in 
cultured cel l  obtained from a Chinese ham ter ovar E. B.  Russo, Burnett, Hal l  and 
Parker, 2005 ). Tn ub equent stud ie r suit of  everal in vi 0 experiments ha e 
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upported the inv Ivement o f  5 -HTl receptor in  the effect of  CBD (Campos et a I . ,  
20 1 2) .  t h igh � concentrat ions 1 0- 1 00 � M ), CBD has also been shown to interact 
with other G-protein coupled recept rs such as 5 HT2 and opioid receptors in an a l losteric 
mrumer ( E .  B. Ru 0 et aI . ,  2005�  Kathmrum, et a I . , 2006) .  
c .  E ffect  of  ca n n a b i d io l  o n  eco n d  m essenger : 
alcium i con ider d one of the most important second messengers i nvolved in  
the regulation oh ariou cel l  functions, such as  muscle contraction and the release of 
neurotran mitter . I t  has been hO\ n that CBD treatment i ncreases intracel lu lar 
concentrat ion of Ca2+ in  cultured h ippocampus neurons ( Drysdale, Ryan, Pertwee and 
Platt, 2006; Ryan, Drysdale, Lafourcade, Pertwee and Platt, 2009) .  I n  another study, the 
ant i -epi leptic acti ity of CBD has been suggested to be due to i ts bidirectional regulatory 
role  on intracel l ular Ca2'" levels  ( Ryan et a 1 .  2009) .  In another i nvestigat ion, it was 
proposed that CBD i ncreases intracel lu lar Ca2+ levels under normal physiological 
conditions, but decreases Ca2+ level s  under highly excitable condit ions (Mato, V ictoria 
anchez-Gomez and Matute, 20 1 0; Rao and Kam i nski,  2006) .  This action of CBD was 
bel ieved to be due to the regulation of ci+ transport in mitochondria whic h  acts as a s ink 
for i ntracel lular Ca2+ ( Ryan et a I . ,  2009). 
I n  addi tion to its influence on intracel lu lar stores, CBD also acts on act ive ci+ 
transport proteins such as Ca2+ -ATPase i n  myocytes (Gi lbeli, Pertwee and Wyl l ie, 1 977) 
and neurons (Gi lbert et a I . ,  1 977;  Ryan et a I . ,  2009) .  The highly l ipoph i l ic nature of CBD 
grants i t  easy access to  i ntrace l lu lar targets such as  cel lu lar organel les (endoplasmic 
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ret iculum and mitoch ndria) and intrace l lu lar! located nzymes that contribute to CBD­
induced al terat ions in intracel l ular a2+ levels Col l ins and Haavik,  1 979). 1 n  this context, 
i t  i imp rtant to note that, the [unctions of various Ca2+-acti ated enzyme uch as 
pho phol ipa e (PL ) ( Howlett, cott and Wilken, 1 989),  phosphol ipaseA2, 
l ipoxygena e (Takeda, sami .  Yamamoto and Watanabe, 2009) and Pho phokinase C 
(PK ) ( H i l l ard and uchampach. 1 994 ; White and Tansik, 1 980) are a lso modulated by 
loy �M concentration of CBD.  
In  addition to a2+ . CBD acts on the uptake process of several neurotransmitters 
(for a review ee Pert wee 2008) .  CBD decrea es the uptake of eH] adenosine in both 
mun n  microgl ia and macrophages, and binding studies show that CBD binds to the 
nucleoside transporter (Can-ier, uchampach and H i l l ard, 2006) .  The enhancement of 
adenosine ignaling through inhibi  tion of its uptake was suggested as provid ing non­
crumabinoid receptor mechanism by which CBD can decrease inflammation (Can-ier et 
aL 2006) .  
d .  C a n n a b idiol  effects o n  vol tage-gated ion c h a n nels :  
Earlier studies of motor neurons showed that CBD depresses the ampl i tude of 
action potential suggesting that i t  inhib i ts the function of neuronal voltage-gated N a + 
channels (Turkanis and Karler, 1 986) .  However, there has been no further study 
i nvestigating the effect of CBD on Na + channels .  Another study indicated that CBD 
increased the L-type Ca2+ cun-ent recorded in the h ippocampal neurons ( Drysdale  e t  a I . ,  
2006) .  Similarly to  these Na channels ,  there have been no  further studies investigating 
the actions of CBD on L- type Ca2+ channels .  On the other hand, the effect of CBD on T­
type voltage-gated Ca2+ channels has been i nvestigated in recent years. I t  has been shown 
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that 'BD inhibit  di fferent ubt pe f a 3 fami l  . channels ( Ross. apier and onnor, 
2 08) .  
e.  a n n a bid io ]  effect o n  l iga n d -gated ion  c h a n nel : 
In  IIE K-293 c 1 1  e .  pre sing glycine receptors, CBD showed a po i t ive a l losteric 
modulatory effect in a low �lM concentrat ion range ( Ahrens et a I . ,  2009). The EC50 
values for the potentiat ing effects of CBD were 1 2 . 3  � M  for al and 1 8 . 1  �M for a 1 � 1  
ubun i t  combinations. Direct activat ion of gl c ine receptors was also observed at CBD 
concentrations above 1 00 �M. S imi lar! , g lyc ine-mediated currents recorded in  dorsal 
horn neuron of rat pinal cord l ices were potentiated by CBD appl ications ( Xiong et a I . ,  
10 1 1 ) .  Furth r i nve t igations ind icated that mutat ions of the a 1 subunit  TM2 serine 
residue to i soleucine abo I i  hed the co-act ivation and the d irect act ivation, of the glycine 
re eptor b, CBD ( Foadi et a I . ,  20 1 0) .  I n  i n  ivo e x p  riments, i t  has been shown that 
ystemic and i ntrathecal administration of CBD signi ficantly suppressed chronic 
inflammatory and neuropathic pain without causing apparent analgesic tolerance in 
rodents ( Xiong et aI . ,  20 1 2) .  The analgesic potency of CBD and 1 1 ,  s imi larly structured 
cannabinoids is posit ively correlated with potentiation of the a3-subunitglyc ine receptor. 
I n  contrast, analgesia induced by these cannabinoids is neither correlated with thei r  
binding affin i ty for CB 1 and CB2 receptors nor with their psychoactive side effects. 
Furthermore, N M R  analysis revealed a d irect i nteraction between CBD and S296 in the 
th ird transmembrane domain of purified a3 GlyR.  More important ly,  the C BD-induced 
analgesic effect was absent in mice lacking the a3 subuni t  from the glycine receptor 
suggest ing that the a3 subuni t  mediates glycinergic CBD-induced suppression of c hronic 
pain ( Xiong et a I . ,  20 1 2 ) .  
Another l igand-gated ion channel reported to be modulated by CBD is the a7-
nicotinic chol inergic receptor (Mah goub et a I . ,  20 1 3 ) .  It was shown that the function of 
human a7-nicot inic receptors expressed in  enopus oocytes was inhibited b CBD with 
an I 50 value of 1 1 . ' p M  in  a non-competi t ive manner. S igni ficant ly .  the 5 -HT3 
recept r. with tmctural imi larities to the a7-nicot inic receptor was also shown to be 
inhibited in xenopus oocyte and H EK-293 cel l s  in  an al losteric manner ( K .  H .  Yang et 
a l . .  2 0 1 0) .  
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1 .4 .2 C l i n ica l  App l icat ion 
a. n t i- i n fl a m m a tory act ion 
s the most abundant non-ps choacti e cannabinoid in the plant.  the anti­
in flammatory actions of BD and its analog have been studied e tensi ely in  recent 
years ( Burste i n  and Zurier, 2009; Booz, 20 1 1 ) . CBD reduces jo int i n flammation in 
col lagen-induced arthr i t is  in  mice (SwllariwaJ la et a I . ,  2004) and carrageenan paw edema 
in rat (Costa et a1. 2004) .  I n  addit ion oral admin istration of CBD (2 .5-20 mglkg) 
reduce neuropathic and inflammatory pain in rats. This effect is reversed by vani l loid 
but not b B receptor antagonists (Costa, Trovato, Comel l i ,  Giagnon i and Col leoni ,  
2007). CBD also reduces i ntesti nal i n flammation in  mice (Capasso e t  a I . ,  2008).  I n  
add ition to i ts abi l i ty to suppress production of the i nflammatory c ytokine TNFa, CBD 
appears to  exert anti - inflammatory pressure by suppressing the  fatty acid amidohydrolase 
(FAAH),  thereby increasing concentrat ions of the ant i - inflammatory endocannabi noid 
anandanli de. Fwiher, i nsight  i nto mechanisms whereby CBD exerts therapeut i c  effects 
was provided by experiments which indicated that CBD attenuates i nflammation i nduced 
by high g lucose levels i n  d iabetic mice (Rajesh et a I . ,  2007). Spec ifical ly,  CBD treatment 
reduces m i tochondrial superoxide. i nducible ni tr ic oxide synthase, nuclear factor kappa � 
activation, and transendothe l ia l  migration of monocytes ( Burstei n  and Zurier, 2009; 
Booz 20 I 1 ).Another potent ial therapeut ic use of CBD may lie in its abi l ity to counter 
some undesirable effects of THC (sedation, psychotropic effects, tachycardia), thus 
suggesting that if given together with THC, i t  may al low h igher doses of TH C (E .  Russo 
& Guy, 2006) .  THC and CBD have been adm i ni stered as an oral mucosal spray to 5 8  
patients with rheumatoid  arthrit is  (B lake, Robson H o ,  Jubb and McCabe, 2006). Treated 
patient had a igni ficant reduct ion in  pain and an improvement in sleep compared to 
patients given a placebo. 
b. e u ro p rotect ion 
I n  earl ier tudie . BD has been sho\.' n to normal ize glutamate homeostasis  
( Hamp on et a I . ,  2000: E I -Rem s et a l . .  2003), reduce oxidative stress ( Hampson, 
Grimaldi ,  xelrod and Winle 1 998:  Marsicano, Moosmann, Hermann, Lutz, and Behi ,  
2002), attenuate gl ial  activation and the occurrence of local i n flammatory events ( Ruiz-
aldepena et a I . ,  �O 1 1 : Mru1in-Moreno et a I . ,  20 1 1 ) . It appears that there may be two 
key mechanisms underlying the neuroprotective effects of CBD. The first is the 
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capabi l it} o f  CBD to re tore the normal balance between oxidative events and antioxidant 
endogenous mechani sms ( Pemandez-Ruiz, 20 1 2) that are frequent ly disrupted i n  
neurodegenerati ve d isorders. thereby enllancing neuronal survival . The second i s  CBD as 
a neuroprotect ive compound, and i ts anti - inflammatory act ivity.  The ant i - in fl ammatory 
effects of CBD are related to the control of microgl ia l  ce l l  m igration and the toxic i ty 
exerted by these cel l s  i .e .the production of pro- i nflan1l11atory mediators ( Femandez-Ruiz, 
20 1 2) .  
The neuroprotect ive e ffects of  CBD were also evaluated i n  animal models  with 
Parki nson's  d isease, H unt ington's  disease and neonatal ischemia.  Pathological changes 
induced by 6-hydroxydoparnine, a toxic compound that targets catecholan1 inergic cel l s  
were sign ificantly reduced by CBD treatment (Lastres-Becker, Mol ina-Holgado, Ramos, 
Mechoulam and Femandez-Ruiz, 2005 ;  Mechoulam, et a1 . 2002) .  It appears that these 
reductions after CBD treatment were i rreversible,  as they did not recover when CBD was 
halted ( Mechoulanl, Peters, Muri l lo- Rodriguez and Hanus, 2007). CBD was also usefu l  
I I  
in  prnenting beta-am) l id-induced neurodegeneration in  in \ ' i  0 and in  vi tro models  of 
Alzheimer disea e ( Fernandez-Ruiz, 20 1 2) .  I ncreased production of reactive oxygen 
pecie , l ipid perox idation, D A fragmentat ion, and intracel lular Ca2+ concentrat ions 
induced by b ta-amyloid pept ide were signi ficantly reduced after CBO treatment of P 1 2  
cel l ( lm'one et a ! . ,  2004) .  
BO ha a lso been shown to be prote ti e against neuronal damage due to 
ischemia ( Hamp on et a l . ,  2000). In rats ubjected to middle cerebral artery occl usion, 
infarct iz and neurological impai rment were reduced by 50-60% by CBO.  imi larly, 
po t-i chemic admini  tration of CBO protected against hyperlocomotion and neuronal 
inj ury fol lowing middle c rebral artery occ lusion in gerbi l s  ( Braida et a I . ,  2003).  
FUl1hermore, it was recently shown that CBD treatment reduced the infarct volUlue in  
brain ischemia, and that th i  effect wa independent of cannabinoid receptor type 1 and 
transient receptor potential V I ,  but sensitive to the 5 -HT I A  receptor antagonist, 
WA Y I 00 1 35 ( Hayakawa et a I . ,  2004; Mishima et aI . ,  2005) suggesti ng that activation of 
5 -HT I A  receptors mediate the neuroprotect ive effects of CBD.  
c .  Trea t m e n t  of n a usea a n d  vom it ing 
Cannabis  has long been used to treat nausea and vomit ing i nduced by various 
drugs and pathological conditions ( Parker, Rock and Limebeer, 20 1 1 ) . Several 
combinations of phytocannabinoids and synthetic cannabinoids have currently been 
approved for use i n  the treatment of chemotherapy-induced nausea and vomiting ( Parker 
et a1 . ,  20 1 1 ) .The reduction of nausea and vomit ing demonstrated by cannabis sativa use 
in vivo and in v itro has been attributed to the presence of THC and CBD.  Un l ike THC, 
which exerts i ts  act ion via C B l receptors, CBD mimics the anti -nausea and anti-vomiting 
propertie of Tl le  through mcchani ms unrelated to CB receptor activation ( Mechoulam 
et a l . .  2007). I ntere ting! y, one of the most effective antiemetic drugs used in cl inics is a 
S HT3 receptor antagoni  t ( Thompson, Chau, Chan and Lumm is, 2006). SHT3 receptors 
belong to a uperfam i ly of l igand-gated ion channe ls  that mediate serotonin- induced 
rapid depolarizat ion in inte tinal neurons and regulate peristalt ic activity of i ntestinal 
mooth mu cJe ( l zzo and Cam i l leri, 2009) .  CBD and THC have been shown to inhibit  
5 HT3receptors ( K. I I .  Yang et al . .  20 1 O)and suppress emesis induced by various chemical 
and ph}' ical st imul i  ( Parker et aI . ,  20 ] ] ) . 
d .  a rd io a c u l a r  effect 
i )  nti-arrh thmic role of BD:  
tudie examining the cardioprotective effect f CBD sho\ ed that CBO has 
antialT, thmic effects after an isch mic reperfusion inj ury ( Walsh, Hepburn, Kane and 
Wail1\\'Tight, 20 1 0).  In model of myocardial infarction fol lowing l igat ion of the le ft 
anteri r de cending coronary arter , i n vivo treatment with CBD resulted in a reduction 
in  infar t ize ( Raje h et a I . ,  20 1 0) .  This finding ha been attributed to an immuno­
modulatory iT ct in CBD,  inc it \, as accompanied b a reduction in  leukocyte 
in fi l trat ion and interleuk in 6 concentrations. A single dose of CBO given 1 0  minutes 
prior to i chemia or reperfu ion resulted in a reduction in infarct s ize, and a signi ficant 
reducti n in the incidence of entricular tachycard ia and total number of ventricular 
ectopic beats ( tanley, H ind and 0' u l l ivan, 20 1 3 ). 
The C B  1 receptor antagonist, AM25 1 , also demonstrates antiarrhythmic 
properties, and treatment with AM25 1 co-administered with CBD has a synergistic 
ffect, suggesting that activation of C B l  receptor i s  proarrhythmic ( Walsh et a I . ,  20 1 0).  
The synergism observed, which persi sts when CB 1 receptors are blocked prior to CBD 
administration, is  suggesti ve  of cross ta lk  between C B  1 and other C B  receptors in  the 
i chemic heart ( Walsh et a I . ,  20 1 O) .Furthermore, CBD significant ly  reduces cardiac 
dysfunction in  mice with diabetes. CBO treatment has been shown to decrease 
myocardial  i nflammation, reduce oxidative stress as demonstrated by a reduction in  
nuclear factor-kB activation, suppress m itogen-activated prote in kinase act ivation, and 
reduce the expression of adhesion molecules and tumor necrosis factor ( Walsh et a l . ,  
20 1 0) .  
i i )  a cular effects of  BDs:  
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BD exert va odi lati e effects as demonstrated by in vivo and in  vitro models 
( ee tan le , l I ind and 0' u l l ivan, 20 1 3 ) .  Howe er. the mechanism and potency of CBD 
appear to  di ffer bet\\ en  variou experimental models .  For example, in some studies, 
BD act through cycloo. ygena e, wh i Ie other e. periment use through CB 1 receptor 
antagoni m and the inhibit ion of pot a s ium ( K+) channel hyperpolarizat ion . The size of 
the blood \' s el i al 0 a key factor, as maximal responses to anandamide ( AEA) are 
ob en'ed in  mal l re istance ve sels  ( 0' uU ivan, Kendal l  and Randa l l ,  2005) .  
I n  rat a rta, t im -dependent CBD va odi latation has been shown to be mediated 
through Gila protein that i sensit ive to pertussis tox in, but is not sensit ive to C B I  
antagoni m or TRPV 1 desensit izat ion (O'Su l l ivan, Sun.  Bennett, Randal l and Kendal l ,  
2009). Addit ional d ifferences are observed in other species. The mechanism by which 
vasodi latation occurs is  al 0 dependent on the type of cannabinoid. For instance, AEA 
and N-arachidonoyl -dopami ne (NADA) exert s imi lar vasodi latation effects in rat aorta; 
however, these effects occur through d ifferent mechanisms ( Stanley, et aI . 20 1 3 ) .  
I t  has a lso been demonstrated that CBD i nduces vasod i latation of segments of 
human mesenteric artery preconstricted wi th  U466 1 9  and endothel i n- l .  The authors of 
th is  study determined that mesenteric artery relaxation i s  endothel i um-dependent, and 
i nvolves CB 1 receptor and T RPV channel activation, NO release and K+ channel 
hyperpolarization ( Stanley et a I . ,  20 1 3) .  
i i i )  Relationship between CBD and peroxisome pro l i ferator-activated receptor 
gamma :  
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L1c lcar receptor ar protein found \ i th in cel l that regulate diverse function . 
such a h meosta is, reproduction, development, and metabol ism.  Pero, i ome 
pro l i ferator-act ivated receptor gamma ( P PARy) belongs to a fami l  of nuc lear receptors 
and play a cruc ial rol in gl ucose and l ipid homeostasis, in addit ion to cel l prol i ferat ion, 
cel l  d i fferentiation, and inflammatory respon e ( B ishop-Bai le , 2000; Hsueh and 
Bruemm r, 2004).  There i e idence to sugge t that cannabinoids bind to and activate 
PP  Ry, thereby cau ing  PPAR-mediated responses. THC,  which is  the major component 
of cannabis, cause time-dependent endothel i um-dependent and PPARy-mediated 
vasodi latation of rat aorta. I n  contrast, CBD,  wh ich is a weak agonist of PPARy 
receptors, causes increased PPA Ry transcriptional activity in PPARy-overexpressing 
HEK293 cel l s  (Hsueh and Bruemmer, 2004) .  
ince CBD is a weak PP Ry receptor agonist, s ide effects nonnal ly associated with 
PPARy receptor activation, such as weight gain, edema, and increased plasma l ipoprotein  
can be avoided. Therefore, CBD may prove to have therapeutic potential as a low affinity 
agonist (O'Sul l ivan et al. , 2009; Walsh et a! . ,  20 1 0) .  
iv) Hemodynamic effects of  CBD:  
Studies on the hemodynamic  effects of  CBD proved inconclusive. I n  some studies, 
a 1 6-mm Hg reduction in mean arterial blood pressure was noted, with no change in heart 
rate (Walsh et aI . ,  20 1 0) .  The authors of this study concluded that the effects o f C B D  are 
best seen in model s  with elevated blood pressure ( Walsh et aI . ,  20 1 0). However, other 
studies did not demonstrate s ignificant hemodynamic changes ( Bergamaschi ,  Queiroz, 
Zuardi and Cri ppa, 20 1 1 ) . 
BD is reported t have an:xiolytic propeliie . and is effecti e as a treatment for a 
fear f publ ic  speak ing. BD r duced heart rate and blood pres ure responses in W istar 
rat c ndit ioned by fear. This response is bel ieved to be mediated by 5HT1A receptors, 
since the effect \ ere inh ibited by the 5HT 'A  receptor antagonist WAY I 00635 (Gomes. 
Re tel and Guimaraes. 20 1 1 ;  Zuard i ,  2008) 
v) Va cular protective effects of  CBD:  
H igh gluc e lev e ls  are known to contribute to endothel ia l  dysfunction in  patients 
\'v ith diabete . High glucose Ie els promote the inhibit ion of endothel ial NO, decrease the 
\'a d i latation effect and increase the vasoconstrictor effects of prostanoids. increase 
uperoxide production. and i ncrease ROS production (Vanhoutte, Shimokawa. Tang and 
Feletou. 2009) .  The aforementioned effects of high glucose were reduced when cel ls  
\"ere co- incubated with CBD ( Rajesh et a I . ,  2007) .  Key elements of atherosclerosis, such 
as monocyte adhesion and transendothel ia l lmigration are reduced by CBD.  Neither CB l 
nor C B2 receptors appear to be responsible for mediating these effects of CBD ( Rajesh et 
a I . ,  2007). Treatment with CBD may also protect against diabeti c  retinopathy. C B D  
prevented vascular hyperpermeabi l i ty at the blood-retinal barrier (BRB),  and protected 
the retina against oxidative danlage, inflammation, and increased levels of cel l  adhesion 
molecules in an in vivo model of  d iabetic retinopathy (E I -Remessy et a1. 2006). 
1 .5 o n  t ra c t i o n  of  Ca rd iac  M u  c le  
ontraction of cardiac mu c le  cel l or  cardiomyoC)1 ho\v certain characteri t ic 
p c i fic to thi mu c1e. For e, ample. contraction of cardiomyocy1.es is  not ini t iated by 
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neuron a in  skeletal mu c le  but by electrical e 'citation originating from the heart ' s  OV,l1 
pac maker. the inoatrial node. \>,'hich gen rate pontane u and periodic act ion 
potent ial . \\'h n an action potential i in i t iated in one cel L current flo\vs through the gap 
j un tion and dep larizes neighboring cel l . I f  depolarizat ion causes the membrane 
potential to be more po i t ive than the thre hold. sel f-propagat ing action potentials occur 
in the n ighboring cel l  as wel l .  Thus. the generation of an action potential i j ust as 
critical for in i t iating contract ion in  cardiac muscle as i t  i s  in  skeletal muscle. but i t  is  
triggered by the s inoatrial node and the spec ia l ized conduction system of the heart 
( Figure 4) .  
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Figu re 4. Anatomy and F u n ction of the H ea rt 's  
E l ectrical System. Johns  Hopkins Medici ne, 
Balt i more, Maryland. 
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eparate tubular tru ture . the tran ver e tubule (T tubule ) .  eros the cel l .  In  the 
cardiac m) oc)1e, the T tubule cro ing occur at th Z- l ine, in contra t to the A-I j unction 
in keletal mu cle. The lumen of the T tubule is  continuou with the extracel lu lar fluid 
'urrounding the cel l and, a in keletal mu cle , the action potential is  propagated dO\\11 
the T tubule ( Ferrantini t a l . .  :20 1 3 ) . djacent cardiac myocytes are joined end-to-end at 
tructure k.nO\\l1 as intercalated disks. These alwaJ occur at a Z-l i ne ( Figure 5 ) .  t these 
point , th cel l membran s form a number of paral le l  folds and are t ightly held together 
by de mo omes. This re u l t  in  strong cel l -to-cel l cohesion, thus al lowing the contract ion 
of one m) ocyte to be tran mirted axially to the next. Gap j unctions exist between cardiac 
mu cle cel l . providing low re istance pathways for the spread of exci tation from one cel l  
to another. 
Z l ines 
I ntelCa lated d tsk 
Fig u re 5. Adjacent  ca rdiac myocytes a re joined end-to-end at 
tructures known as intercalated disks. 
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normal action poten tia l .  Rest ing (4). up troke ( 0), early repolarizat ion ( 1 ), p la-
teau (2) and final  repolarization are the 5 phases of the act ion potent ia l .  A dec l i ne of 
potent ial at the end of pha e 3 in pacemaker cel  I , such as the s inus node, i s  shown as 
a broken l ine .  The i l1\\ ard current . INa, [Ca and I f, are sho\\ n in  ye l low boxes; the 
sod i um-ca lc ium exchanger (NCX) i a lso sho\\ n in yel low. [t is e lectrogenic and may 
generate i l1\\ ard or outward current .  l KAch, [ K  I .  I to, I K ur I Kr, and I Ks are shown in 
gray boxes. The act ion potential  durat ion C APO) is approximatel 200 ms atte l & 
Carlsson, 2006) .  
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1.5. 1 Exci ta t io n-Con t ract ion  Co u p l i n g  
a .  The  e n t ri c u J a r  a c t i o n  pote n t ia l  
3 1  
The cardiac act ion potent ial represents chang s in  the membrane potential due to 
th movement of ion across the cel l membrane through vol tage-gated ion channels, 
pump , and exchangers, and has di sti nct characterist ics in di fferent regions of the heart . 
I n  entricular cardiomyocyte (Amin, Tan and Wi lde, 20 1 0) .  According to kinetic 
propert ies, the cardiac action potent ial i divided into 4 d i stinct phases (F igure 6) .  The 
fir t pha e of the action potent ial is characterized by the act ivation of fast Na + channels, 
which open briefly to produce an infl ux of posit i  e Na + ions caus ing rapid depolarization 
of the ce l l  membrane and an upstroke of the act ion potential . This ini t ial phase i s  cal led 
phase O. Fol lowing phase 0, a brief repolarization is observed at the peak of the action 
potent ial and is  the consequence of both fast Na + channel inactivation and the activation 
of i nit ia l  repolarizing currents. This brief  repolarization phase is  cal led phase 1 .  
Fol lowing phase 1 ,  a long lasting plateau of depolarization ( 1 00-200 ms), named phase 2 ,  
i s  observed. Depolar iz ing currents main ly  l ate Na+ and L-type Ca2+ channels stay open 
and continue to offset repolarizing currents during the plateau phase. Final ly ,  L-type Ca2+ 
channel s  begin to i nactivate and several cardiac K+ channels such as delayed-rect i fier and 
inward-rect ifier K+ channels begi n  to open and cause the repolarization of the membrane 
to resting membrane potent ia l .  This repolmization is cal led phase 3 .  The ventr icular 
action potential i s  regenerative, and continues to excite ventricular cel l s  i f  the st imulus 
exceeds the crit ical threshold for depolarization as determined by avai labi l ity of Na + 
current .  Phase 4 i s  the resting membrane potential and describes the membrane potential  
when the cardiomyocyte i s  not being stimulated. In a great majori ty of contract ing 
cardiomyoc) te pha e 4 ha a lov\' lope ( almo t a horizontal l ine) .  However. in 
pacemak ing cel l s, pha e 4 is unstable ( phase 4 - i the pacemaker potential) .  I n  
pac maker ce l l  (such a th inoatrial node), the membrane lowly depoJarizes during 
phase 4, unt i l  i t  reaches a threshold potential (around AOm V) or unti l it is  depolarized by 
an electrical impulse coming [Tom another cel l .  The reason for this pacemaker potential is  
an increa ed inward current of  sodium (Na +) through vol tage-dependent channels, but 
a lso an increa ed inward a2+ current and a decrease in the K+ outward current. These 
a 4- channel , in cardiac pacemaker cel ls ,  contrary to what usual ly  happens in other cel ls ,  
open \Vh n the vol tage is  more negat ive. 
b. Ca lc i u m- i n d u ced c a lc i u m  reJease 
The action potent ia l  propagates along the sarcolemma, i nvades the transverse 
tubules and causes release of Ca2+ from internal Ca2+ store such as sarcoplasmic 
ret iculum and leads eventua l ly  to the in i tiation of musc le contraction. This sequence of 
events, beginning with act ion potent ial generation and result ing in  muscle contraction is 
known as excitation-contraction coupl ing ( Figure 7) .  I n i t ia l ly  depolarizat ion caused by 
the action potential act ivates voltage-gated L-type Ca2+ chmmels which moe concentrated 
in the Tubules ( Shepherd and McDonough, 1 998) .  Act ivation of these chan nels i nduces a 
confonnational change i n  the ion ch31mel structure and causes a subsequent influx of 
Ci+i nto the cel l .  This influx of ci+ is  known as  spm·klets (Navedo and Santana 20 1 3 ). 
The presence of sparklets i s  not sufficient to cause activation of the contract i le 
machi nery. However, i t  i s  sufficient to in i t iate the release of furtherCa2+from intrace l lular 
stores by interact ing with ryanodine receptors ( Ry Rs) on the sarcoplasmic ret iculum. The 
local ampl ification of intracel lular Ca2+ mediated by RyR activation i s  also known as a 
a2 park ( Feamley, Rod fick and Bootman, 20 1 1 ) , and i es ential fOf causing a a2+ 
transient that acci ates the contract i le myofi l ament result ing in muscle contraction. I n  
general ,  yto o l ic Ca2+ i n fl u. in  v ntricular cel l s  occurs main ly  through two distinct 
source' .  b ut  8 to 23°'0 of a2+ enter extracel l ularly through the opening of L-type 
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a2+ channel and 77% to 92% of total Ca2+ employed in  muscle  contraction is  released 
from the arcoplasmic ret iculum through RyRs, although some inter-species differences 
d e. i t ( Ber , 2008) .  Th contri bution of NCX and mitochondria to cytoso l ic  Ca2+ is  
u ual l )  not mor than 1 % ( Bel'S, 2000). Fol lowing its release, Ca2+ is  pumped back i nto 
the sarcopla mic ret iculum by a Ca2+-ATPase pump and also removed from the cel l  via 
the a ICa2+ exchanger located at the plasma membrane ( Wang, Song, Lakatta and 
Cheng, 200 1 ) . 1 n  cardiac mu c le ,  the act ivi ty o f a  Ca2+-ATPase in the sarcoplasmic  
ret iculum is inhibi ted b the regulatory protein phospholam ban. When phospholamban i s  
phosphorylated by cAMP-dependent protei n  k inase, i t s  abi l i ty  to inhibit the Ca2+ -A TPase 
i lost.  Thus. act ivators of cAMP-dependent protei n  k inase, such as the neurotransmitter 
epinephrine, may enhance the rate of cardi ac myocyte relaxat ion.  
Smco :-::1il 
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Figure 7. Cardiac excitation con t raction coupl i ng. I n  et ho\\ the t ime course of an action 
potent ia l .  Ca� transient and contraction mea ured in  a rabbit \'entricu lar I11)OCy1e at 3 7 °C. CX, 
a ICa2 exchange: ATP. ATPase; PLB. phospholamban; SR, sarcopla m ic ret icu lum ( Bers -
2002) .  
Calci u m  C h a n n e ls 
Due to the imp0l1ance of Ca2+ in  various vi tal cel lular e ents such as muscle  
contraction. neurotransmitter release, and exocytosis;  the  regulation of Ca2+ entrance 
through \'oltage-gated Ca2� channels has been studied in deta i l  ( Catteral l ,  Perez-Reyes, 
nutch and Striessnig. 2005 ). According to phal111acological and biophysical 
characteri stics three different types of Ca2+ channels  have been characterized.  These 
different types of Ca2+ channe ls  are summarized in Table 2 .  
Tn  the heart. both T-t) pe and L-t)p 2� a channels  have been ShOVv11 to be 
exprcs ed (Zhou and January, \ 998) .  HO\,v ever. T-type Ca2+ channe ls  appear to be 
loca l ized mainly in  cel l involved in heart rhythm and automatici ty such as pacemaker 
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and atrial ce l l . \'v'hi le  L-type Ca2+ channels are local ized main ly i n  ventricular myoc)tes. 
mentioned abo e. due to their I w acti ation kinetics, L-type Ca2+ channels  require 
ng depolarizations lasting \ 00-200 m . After the acti vation process, L-type Ca2+ 
channels are inactivated by "ari us factors which inc lude time, voltage, cytoso l ic Ca2+ 
concentration and calmodul in  ( Bers, 2000). 
Table 2.  la  ification o f  calciu m  channel 
32+ a l  pec i fic P r i n c i pa l  p h  
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i o logica l  fu n c t ion 
c u r re n t  <, u b u n i t  blocker 
type 
L 
P/Q 
R 
T 
a, 1 . 1  D I I Ps Exc itation-contraction coupl ing in Hypokalemic period ic 
skeletal m uscle, regu lation of paralysis 
transcript ion 
Ca, 1 .2 m-I Ps Exc itat ion contraction coup l i ng in Ti mothy syndrome: card iac 
cardiac and mooth muscle, endocrine arrhyth m  ia with 
secret ion, neuronal Ca2+ transients in developmental abnormal i t ies 
c e l l  b d ies and dendrites, regu lation of and autism spectrum 
enzyme acti ity, regulation of d isorders 
tran cription 
Ca, 1 .3 D l l Ps V isual transd uct ion Stat ionary n ight b l i ndness 
a, 1 . 1 (j)- T,,-G V I A  eurotransmitter release, Dendritic 
Ca�+ transients 
Ca,:2 . 2 w-Agatoxin Neurotransmitter release, Dendrit ic Fam i l i al hemi plegic 
Ca2+ transients m i graine, cerebe llar atax ia 
a,2.3 j -482 Neurotransmitter release, Dendritic 
Ca2+ transients 
Ca,3 . 1  one Pacemaking and repet i t ive firing 
a\ 3 .� Pacemak ing and repeti t ive firing Absence seizures 
a, J . 3  
bbre\ iat ions : DHP, d i hydrop r id ine; GJ-CTx-GVI A, GJ -conotoxin  G V I A  from the  cone sna i l  
Conusgeographu : X-482, a s ntbet ic  vers ion of  a pept ide tox in from the  tarantu la 
H) terocratesgigas (CattCl"aJl, 2 0 1 1 ). 
s shm n in Figure 8, the L-type Ca2+ channel consi ts of 4 subunits: the major 
pore-fonning a [  subuni t  and a ariety of accessory subunits .  Thea [ subuni t :  Fonned of 4 
homologous domains ( I- IV) ,  each consisting of 6 transmembrane (TM) hel ices joi ned by 
intracel lu lar l i nks. The loops between TM5 and TM6fonn the channel pore, while TM4 
contains argin ine or l ysine residues that fonn the voltage sensor, which is  thought to 
move or twist as the membrane potential changes. 
Ion selectivity i s  govemed by a glutamate residue preserved in  the pore-l in ing 
loop of al l 4 domains ( Dolphin, 2006; 1 .  Yang, E l l i nor, Sather, Zhang and Tsien, 1 993) .  
Tvv'o Ca2+ ions enter the ce l l  at  a t ime, are regulated by 2 glutamate residues and flow 
down the Ca2+ concentration gradient (Heinemann, Terlau, Stuhmer, I moto and Numa, 
1 992; J . Yang et aI . ,  1 993) .  L anthanum, cobalt and cadmium inhibit  the a[ subuni t  
( 0 Iphin,  2009). Expres ion of the a(  subun it \v ithout the aux i l iary subunits, resu lts in 
low L-type a2+ channel expre sion Ie el . and abnonnal vol tage and kinetic properties 
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in the channel . The � ubuni t is  located o n  the intrace l l ular side of the channel .  I t  interacts 
\\- ith the a ubunit  through th a-i nteract ion domain ( 1 0), a guanylate cyclase-l ike 
region located behveen domains I and I I  ( atteral ) '  20 1 1 ;  Pragnel l  et a l . .  1 994). The A I D  
ha a wel l -con en'ed gene equence and also occurs in  N-type and P/Q-type 
Ca2+ chann I ( Richards, Butcher and Dolphin, 2004) .The � subunit  al ters channel 
expres ion. voltage dependence, and gat ing kinetics. Four � subunits have been c loned, 
and al l except for �2a hyperpolarize act ivation and steady-state i nact ivation of Ca2+ 
( Dolphin.  200 "' ) . The a2b subuni t  is an accessory subunit consisting of the 
8tran membrane domain. and a2. an extrace l lular domain .  Four a2 isof01111s have been 
ident i tled. Co-expression of an subunits increases Ca2+ channel expression and function. 
The y subunit is  a 30 to 40kD i nh ibi tory protein  consisting of 4 TMa helices (Takahashi ,  
eagar, Jones, Reber and Cattera l l ,  1 987) .  
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Fig u re 8. Calc ium cha n nel s u b u n i ts. tructure of calc ium channels sho� ing the five subunits a. 
�. a28 andy ( F igure modi fied from Cattera l l ,  20 1 1 ) . 
ecretion of catecholami ne from the adrenal medul la  and the autonomic nervous 
y tem t imulate p-adrenergic receptors v ia adenyJcyc1ase. cAMP, and protein kinase A 
(PKA)  to produce positive chronotropic. i notropic and lusi tropic effects. Cardiac L-type 
Ca2- channel are modulated through the p-adrenergic/cAMP signal ing pathway: a I and p 
ublmits are phosphorylated by PKA ( De Jongh et a I . ,  1 996; Haase. Bm1eL Karczewski .  
forano& Krause. 1 996: H e l l  e t  a l . .  1 993 :  Puri. Gerhardstein,  Zhao. Ladner and Hosey. 
1 997) .  p-adrenergic receptor act ivation causes a 2 -fold i ncrease in  the L-type Ca2+ current 
by increasing the number of channels  and their activation probabi l i ty .  The latter is  
mediated through PKA-mediated phosphorylation of the Ca, 1 .2 ( a l c-subuni t )  chmmel 
protein and/or associated proteins (CatteralL 20 1 0) .  As opposed to the adrenergic system, 
reciprocal control over Ca2� entry is provided by ACh. acting through mu carinic Ach 
receptors, rai ing intracel lu lar cGMP concentrat ions and cau ing cG I P-dependent 
pho phorylation of the L-t pe a2+ channel . In tum, the cGMP-dependent 
ph phol) lal ion of L-t pe a2+ channels ,  at s i tes di t inct from tho e phosphorylated by 
the c MP-dep ndent kinase, cause a decreas in Ca2+ i nflux during the cardiac action 
p tential and thu a decrease in  the force of contraction. 
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1 .5.2 S a rcopla m ic Ret ic u l u m  a n d  Rya n o d i n e  Receptor 
1 he arc plasmic ret iculum ha man, roles in  the regulation of muscle  
contraction and intracel l ular a2+homeo ta is. The release of Ca2+ from this organel le 
cause increa ed a2+le els to activate ari u a2+ dependent enzymes such as 
calm dul in and adenyl c c lase ( Fearnle et a l . .  20 1 1 ). I t  i s  also the s i te of  phosphol ip id 
gen rat ion and i t  communicate with other i ntracel l ular organel le such as the 
mit  hondria. Hov, e\ er. i t ' s  mo t important function is  the regulation of Ca2+ 
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homcostasi . I t  i wel l  kI10'v\11 that cyto l ic Ca2+ levels  dur ing rest ing conditions are in 
the nM range. w hi le  extrace l l ular Ca2+concentrat ions are much higher (�M range) .  As 
mentioned above. fol lowing an action potential ,  cytosol ic  Ca2+ concentrat ion increa es 
and act i v ates ryal10dine receptors. which ampl i fy the Ca2+ signal and stimulate Ca2+­
i nduced Ca2+release. everal  isofom1s of ryanodine receptors ( RyR) have been ident ified :  
RyR I is  expre sed i n  skeletal musc le, RyR2 in  cardiac muscle  and the brain, and RyR3 in  
the brain ( Lanl1er. Georgiou. Joshi and Hami l ton, 20 1 0) .  Al though the ryanodine receptor 
is a protein of till SR membrane, 80% of this protei n  is located in the c ytoplasm. The 
i ntracel l u lar position of ryanodine d iffer from one cel l type to another (Zucchi and 
Ronca-Testoni ,  1 997). It can be directly attached ( as in skeletal musc les) or detached (as 
i n  cardiac muscles) to the L-type Ca2+ chanl1e l .  I n  skeletal muscle, direct interaction of 
the ryanodi ne receptor wi th  the L-type Ca2+ channel  causes fast excitation-contraction 
coup l ing and rapid in i t iation of skeletal musc le  contraction (within a few minutes). I n  
cardiac muscle  o n  the other hand, excitation-contraction i s  a relative ly  slow process 
(within hundreds of m inutes). Function of the ryanodine receptor is also regulated by 
several l i gands, i nc luding Ca2+, calmodul in  and caffeine (Feamley et a ! . ,  20 1 1 ). 
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1 .5 .3  T h e  Con t ra c t i le M a c h i nery 
y fi laments occupy about half of the cel l  volume in  mammal ian ventricular 
myoc) tes. As with skeletal muscle, cardiac m oc tes conta in  the contrac6ie prote ins 
act in (thi n fi lament ) and m osin ( thick fi lament ) together with the regulatory proteins 
troponin and tropom 0 in .  In their structural configuration, the thin filament comprises 
act in with a piral ing ba kbone of tropom 0 in,  along with troponin complexes (C, I and 
T) that occur at certai n  intervals ( Figur 9). Each act in  fi lament consi sts of a site where 
myosin can bind, but the e sites are blocked by tIopom osin when cytosol ic  Ca2+ 
concentration i low. When cytosol ic  Ca2+ concentrat ion increases due to Ca2+ release, 
Ca2+ binds to troponin C causing tropomyosin  to shi ft, thereby exposing the myosin 
b inding ites. Adenosi ne d iphosphate (ADP) and phosphate, present on the myosin head 
since the previou movement cyc le, are released when myosin attaches to myosin binding 
sites on the act in  ftlaments. The energy generated in  the head i s  used to in i t iate upstroke 
and s l id ing, unt i l  the act in-myosi n  complex is l iberated by adenosine tripbosphate (A TP) 
bind i ng the m osin head. ATP i s  hydrolyzed to ADP and phosphate releasing energy 
that is stored in the myosin  head to be used in the subsequent stroke. 
/ Tn-C T I n -
myosin rod section 
/ S1 
/TropomyoSin 
--Actin 
/LC-1 
LC-2 
/ 
C Prote in ___ S2 
- - -) - - -) 
- - - -. - -
force and/o r 
shorte n i n g  
Fig u re 9 .  Sarcomere structu re. The t h i n  fi l ament i composed o f  act in ,  tropom) os in ,  and the 
tropon in  \\ h ich cons ists of the tropon i ns Tn-T. Tn-C. and Tn- I .  The th ick fi lament is composed of 
m) o in. a globu lar head port ion (S l ). a h inged sta l k  region (S2)  and a rod sect ion. S l  cons ists of 
an A TP h) droJ) is domain  and the act in  b ind ing doma in.  i t  is assoc iated w ith  the l ight-chain J 
and 2 ( LC- l � LC-2) ( Hamdani et aL 2008) .  
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1 . 5.4 Calc i u m  en i t i v i ty of Myofi l a m e n t  
The tenn m ofi lament Ca2.,- ensiti i t  came into u e a fter i t  was d i  co  ered that 
the force of contracti n is n t only d pendent on the free cyto ol ic  Ca2+ concentration, 
but al 0 on the affinity of troponin C for Ca2+. Bio hemical and physiological 
experiment have hovm that several factor affect m ofi lamentCa2+ sen i t ivi ty, 
inc luding pI  L temperature, ionic trength and tropon in  1 phosphorylation ( Ruegg, 2003 ). 
Furthennore,  th se factors can be categorized b whether they affect thick or thin 
fi laments ( Bers, 200 1 ). Factor that affect thick fi laments tend to affect the relationsh ip  
betv,:een intrac I l u lar Ca2+ concentration and the extent of myo in  l ight chain 
phosphorylation. Wherea factors that affect thin fi laments, affect phosphorylation of 
myo in l ight chain and force generation due to contract i l e  proteins ( Bers, 200 1 ) . 
C h a pter 2 :  M e t hod 
2.1 Ven t ricu l a r  M ocyte I o J a t ion  
entricular myo yte were i solated from adult male Wistar rats (264 ± 19  g) 
according t pr iously described t chnique . This tudy was carried out i n  accordance 
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\ i th the recommendation in  th Guide for the Care and U se of Laboratory Animals from 
th ati  nal In ti tute of Health .  The protocol was approved by the Committee on the 
Ethic of nimal Experiment at the Uni ted Arab Emirates Universi ty.  In brief, the 
animals were euthan ized u ing a gui l lotine and their hearis were removed rapidly and 
mounted for retrograde p rfusion according to the Langendorff method ( Figure 1 0) .  The 
heart were perfused at a constant flow of 8 ml g heart- I min- I and at 36-37 °C with a 
sol ution contain ing (mM) :  1 30 NaCI ,  5 .4 K 1 , 1 .4 MgCh, 0 .75 eaCb, 0.4 NaH2P04, 5 
HEPE , 1 0  glucose. 20 tauri ne and 1 0  creatine set to p H  7 .3  with NaOH. When the heart 
had stabi l ized perfu ion was continued for 4 minutes with a Ca2+-free iso lat ion solution 
containing 0 . 1 mM EGT A, and then for 6 minutes with cel l  isolation solution containing 
0.05 mM Ca2+, 0.75 mglml col lagenase ( type 1 ;  Worthington B iochemical Corp. , USA) 
and 0.075 mglml protease (type X l  V ;  S igma, Germany).  Ventric les were excised from 
the heart, minced and gent ly shaken i n  col lagenase-containing isolation solut ion 
supplemented with 1 % BSA. Cel l s  were fi ltered from this solution at 4 minutes i ntervals 
and resuspended in an i solation solut ion contain ing 0 .75 m M  Ca2+ . 
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2.2 l ea u re m e n t  o f  Ven t r·i c u l a r  Myocyte  h o rten i n g  
Ventricular m 0 ytes were al lowed t o  settle o n  the glass bottom o f  a Persp x 
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chamber m unt d n the tage of an inverted micro cope ( xi overt 35 ,  Zeiss, Germany). 
M y o  yte were uperfu ed ( "-5 mllmin) with normal Tyrode T) contain ing (mM) :  1 30 
a L 5 K L 1 19  b, 1 0  glucose, 5 HEPE . 20 taurine, 1 0  creatine and 0 .75 CaCl2 (PH 
7 A).  hortening of myoc tes was recorded using a video edge detection system (VED-
1 1 4, ry tal Biotech, U A) according to pre iOLls ly  described techniques ( Howarth, 
Qure h i  and White, �002). Re t ing cell length ( RCL) t ime to peak (TPK). time to hal f 
(TH LF) relaxation and ampl i tude of shortening (ex pre sed as a percentage of resting 
cel l  length) were mea ured in  electrical ly stimulated ( I  Hz) myocytes maintained at 3 5-
36 °C. Data was acquired and anal zed with signal a erager software v 6 .37  (Cambridge 
Electronic De ign, K). Experimental solutions were prepared from stock immediately 
prior to each experiment . 
2 .3 Meas u re m e n t  of  I nt racel l u l a r  Ca2+ Concen t ra t ion 
Myocytes were loaded with the fl uorescent indicator fura-2 AM ( F- 1 22 1 ,  
Molecul ar Probes, USA) as described ( Howarth et a I . ,  2002) .  I n  brief, 6 .25 �l of a 1 mM 
stock sol ution of fura-2 AM (dissolved i n  dimethyl sulphoxide) was added to 2 . 5  ml  of  
cel l s  to  gi e a fina l  fura-2 concentration of 2 .5  �M.  M yocytes were gent ly shaken for 
1 0  minutes at 24 °C (room temperature) .  After loading, myocytes were centrifuged, 
washed with NT to remove extrace l lu lar fura-2 and then left for 30 min to ensure 
complete hydro lysis of  the intrace l lu lar ester. I ntracel lu lar Ca2+ was measured according 
to previously described techniques ( Howarth et a I . ,  20 1 1 ) . Myocytes were alternately 
i l l uminated by 340 and 3 80 nm l ight using a monochromator (Cairn Research, UK) 
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\\ hich hanged the excitation l ight every 2 minutes. The re ul ting fluorescence emitted at 
5 J 0 nm was recorded b) a photomult ipl ier tube and the ratio of the fluorescence emitted 
at the t\\ 0 excitation wavelengths (340/3 80 ratio) wa calculated to pro ide an index of 
intracel lular a2+ concentrat ion. R sting fura-2 rat io, t ime to peak (TPK), time to half 
(TH LF) deca of the a2+ tran ient, and the ampli tude of the Ca2+ transient " ere 
mea ured in  electrical ly sti mulated ( 1  Hz) myocytes maintained at 35-36 0c.  Data were 
acquired and analyzed wi th ignal averager software 6 .37  Cambridge Electron ic 
De ign, UK) 
2 ..1  M ea u re m e n t  of Sarco pla  m ic Ret icu l u m  Ca2+ Conten t 
arcopla mic ret iculum ( S R) Ca2+ release was asses ed using previously described 
techniques ( Howarth et a l . .  2002). After establ ishing a teady state of Ca2+ transients i n  
electrical ly  st imulated ( 1  Hz) myocytes maintained at 3 5-36 °C and loaded with fura-2, 
stimulation was paused for a period of 5 seconds ( Figure 1 1 ) . Caffeine (20 mM) was then 
appl ied for 1 0  econds using a solution switching device customized for rapid solution 
exchange. E lectri cal stimulation was resumed and the Ca2+ transients were al lowed to 
recover to a steady state. S R-re leasable Ca2+ was assessed by measuring the area under 
the curve of the caffeine-evoked Ca2+ transient. Fractional release of SR Ca2+ was 
assessed by comparing the ampl itude of the e lectrical ly evoked steady state 
Ca2+transients with that of the caffeine-evoked Ca2+ transient and refi l l ing of the S R  was 
assessed by measuring the rate of recovery of electrica l ly  evoked Ca2+ transients 
fol lowing the appl ication of caffeine. 
Figu re 1 1 . The record ing  system used for v ideo edge detect ion and Ca2+ im aging 
u periment : The s) tern inc lude an ant i - \  ibration table ( A ). a Farada. cage ( B ). an 
im erted micro cope ( C) .  a ce l l  superfusion S) tern ( D) \\ ith a temperature control 
) tern ( E ). a \ ideo edge motion detector ( F) .  a microfl uore cence photometr; 
s) tem (G)  and an electrical st imu lator ( H ) . 
2.5 A se s m e n t  of Myofil a m e n t  Sens i t iv ity to Ca2+ 
In ome cel ls  shortening and fura-2 rat io were recorded simultaneousl 
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Myofilament sensi t iv i ty to Ca2+ was assessed from phase-plane diagrams of fura-2 ratio 
versus cel l length by measur ing the gradient of the fura-2-ce l l length trajectory during 
late rel a. ation of the twitch contraction. The position of the trajectory reflects the relative 
myofilament response to Ca2+ and hence, can be used as a measure of myofilament 
sensi t ivi ty to Ca2+ (Spurgeon et a l . ,  1 992; Howarth et aI . ,  2002). 
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2.6 W h ole-Cel l Reco rd i n g  
Whole-cel l  recording were performed in  i olated ventricular m ocytes. The 
my c tes were placed in the recording chamber (0 .4 mL)  mounted on the stage of an 
inverted microscope ( K2, 01 mpus, Tok 0, Japan) ( Figure 1 2) .  After ett l ing to the 
bottom of the chamber, ce l ls  wer uperfu ed with an external solution for 1 0  min at a 
rate of 2-3 mL.min- 1 at room temperature. The external solution contained ( in  m M )  1 20 
a I ,  I EGT A, 1 0  MgCb, 1 0  Glucose, 1 0  H E PES,  1 NaH2P04 and 5 KCl .  
ran membrane currents were recorded with a n  axopatch ampl i fier 200 B ( Axon 
In truments, Inc . ,  Fo ter City, CA_ U A) .  The \ hole-ce l l  bath solution conta ined ( in  
m I ) :  95  aCt 50  TE C l ,  2 MgCI2, 2 CaCI2, 10  H E PES and 1 0  Glucose (adjusted to 
pH 7 .35  with aOH ) .  Glass microelectrodes were made using a microelectrode pul ler 
( 10del P-97. utter I nstrument Co .. Novato, CA, U A) ( Figure 1 3 )  by two-stage pul l i ng, 
and had a resistance o f 2 .0-+.0 Mn when fi l led with electrode internal solution 
containing (in mM) 1 40 CsCl ,  1 0  TEACI, 2 MgCh, 2 HEPES 1 MgA TP and 1 0  EGT A 
(adj usted to pH 7 .25 with CsOH) .  Only rod shaped cel l s  with c lear cross-striat ions were 
used for the experiments. Figure 1 4  shows typical ventricular myocytes with patch 
pipette i n  sol ution. After gigaseal formation ( 1 - 1 0  Gn) by suction through a pipette, the 
membrane was ruptured with a gentle suction to obtain  the whole-ce l l  voltage clamp 
configuration. Membrane capaci tance and series resistance were compensated after 
membrane rupture to min imize the duration of capacit ive current.  The experiment was 
conducted under room Temperature (22-24 DC) .  To record L-type Ca2+ cun-ents, the 
external sol ution was changed to the a + -free sol ution in which Na+ was replaced by 
equimolar TEA (TEA--C l ) . The Na+ current was also inactivated at the holding potential -
50 mY.  K+currents were suppressed by substituting K+ by Cs+ .  Computer-generated 
PO\\ er 
suppl) for 
L ight 
A \.opatch 
Ampl ifier 
:200 B 
50 
\ oltage pu lses ,,\  ere programmed using the pC L A M P  I 0.0 sofu� are (Axon I nstruments) .  
e l l  '" i th table calcium current w ere then tested using d i fferent drugs 
Solution 
Figure 1 2. Patch cla m p  etup 
5 1  
Figu re 1 3. Mi cr·oelect rode pu l ler ( model P-97, Sutter I n  tru ment)  
Figu re !-t. Glas elect t'ode fo rming giga eal w i th  ventr icular 
myoc�"te 
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3. 1 E ffect o f  Ca n n a b i d i o l  o n  Ven t ri c u l a r  Myoc te h o rte n i n g  
5 3  
In  ormal T y  r de T) o lution, ampli tudes of m ocyte short ning in  response to 
electrical t imulation ( I  Hz) gradual l y  decreased to 85 -80 % of control during 
experim I1t la  t ing up to 20 minute . 0 further rLuming do n of the shortening 
ampl i tude wa ob erved in  the T ol ution ontaining 0 .02 % DM O. nd,  unless i t  
stated otherwi e, 0 1 0 ( i n  the concentration used in CBD containing solution) was also 
inc luded routinely in the control T o lutions during the shortening and Ca2+ transient 
exp riments. 
In in i tia l  control experiments and in  l i ne with earl ier stud ies conducted under 
imi lar cond it ions i t  has been hown that 0 .0 1 % DMSO did not signi ficantly affect 
contract i le  parameters and Ca2+ CUlTent in rat ventricular myocytes(Sun et a I . ,  20 1 0) .  The 
appl ication of control sol ut ion (NT) contain ing dimethyl sul foxide at the highest 
concentration used in contract i l i ty studies (0 .02 % v/v; used as vehicle for 1 11M CBD) 
caused 1 1 - 1 3  % inhibit ion of the shortening (n=7- 1 0; P<0.05 compared to a 0 t ime 
poi nt) .  
I n  the first set of  experiments, we tested the effect of  CBD on the contracti l i ty of 
acutely isolated rat ventricu lar myocytes. Figure 1 6A shows typical records of shortening 
i n  myocytes superfused with either T ( i n  the absence of CBD NT contained 0 .02 % 
DM 0 i n  a l l experiments) or NT + 1 11M CBD and during washout with NT. The t ime 
frame of the effect of CBD on ampl i tude of shortening i s  shown in  F igure 1 6B .  The 
effect of CBD reached a steady level within 5 m inutes of CBD appl ication. I ncreas ing the 
i ncubation t ime to 1 0  m inutes did not cause any further change in the ampl itude of 
shortening. Recovery from CBD inhibit ion was incomplete during the 5 - 1 0  minutes 
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washout t ime.  1n ummal) , the ampli tude of shortening mea ured after 5 minutes bath 
appl icati n of BD \ as ign i fi cant ly  reduced ( paired He t ;  n= 1 7 · P<O.OS ) by up to 46.4 
± 3 . 1  % in the control ( Figure 1 6  ) .  The effect o f  C B D  increased in  a concentration­
dependent manner. The concentration-re pon e r lationship nomlal ized to maximal CBD 
inhibition indicated that BD suppresse shorten ing of ampli tudes with an ICso of 0.6 
11  I (F igure 1 7) .  mong other contraction parameters measured, resting cel l length 
( R  L), t ime t o  peak and t ime to hal f re laxation \ ere not signi ficant ly  al tered 
( n= 1 7 : P>0.05)  by 1 0  minutes superfusion with C B D .  
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Fig u re 1 6. E ffect of  can nabid iol on ventricu lar  myocyte shorten ing. (A)  Typical records of 
horten ing in  an e lectrica l ly st imu lated ( 1  Hz) ventricu lar myocytes superfused \ i th e i ther NT 
(conta in ing the  eh ic le, 0 .02% OM 0) or T + 1 �M CBO and during washout with NT. ( B) 
Time course of the mean ampl i tudes (AMP) of shorten ing expressed as a percentage of control  
values in veh ic le  (NT + 0.02% OMSO), and i n  presence of CBD ( l  �M).  Myocytes were 
maintained at 3 5-36 °C and superfused with CBO for 1 0  m inutes. (C) Data shown as means ± 
. E . M ., n = 6-8 ce l ls .  * ind icates stat ist ical ly s ign ificant d i fference at the level of P< 0.05.  
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Figu re 1 7. Concentration-i n h i bi tion relat ionsh i p  o f  can nabidiol  effect on t h e  shorten i n g  of 
myocytes. Concentrat ion-response curve for the inh ib i tory effect of C B D  on myocyte shorten ing. 
The data was normal ized to maximal i nh ib i tory effect of C B D  and plotted as a function of CBD 
concentrations.  Data are mean ± S .E .M .  from n = 6-8 ce l l s  for each concentrat ion . 
3.2  ; ffect of  Ca n n a b i d io l  on I n t race l l u l a r  Ca2+ 
I n  the second et f experiment we investigated the effects of 5 minutes bath 
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appl ication [ l )lM CBD on the rest ing intracel lular a2+ Ie el . and on tbe ampl i tudes 
and kinetic f a2+ tran i nt e l ic i ted by electrica l - fie ld stimulation. Typical records of 
a2 tran ient in  a m) oc te superfused witb T (containing 0.02 % DM 0) T + 1 
)lM BD and during wa hout witb T are shown in Figure 1 8  . The effects of  1 )lM 
BD on re t ing fura-� rat io, TPK Ca2+ transient, TH LF decay of the Ca2+ transient and 
AMP of a2+ tran ient are shown in F igure 1 8B-E,  respective ly .  Although, CBD has 
been hO\\l1 to alter intrace l lular Ca2+ Ie eis in various types of cel l s  (see Pertwee. 
2008:Pet1wee. t a l . .  :20 1 0).  appl ication of 1 11M CBD for 5 to 1 0  minutes did not cause a 
signi ficant a l terat ion in rest ing fura-2 ratio, TPK Ca2+ transients, or THALF decay of the 
Ca2 transi nt ( paired (-te t; n= 1 1 - 1 4 cel ls ,  P>0.05 ) .  However, the AMP of the Ca2+ 
tran ient was ignificant ly  reduced by 1 )lM CBD (0 .337  ± 0.043 fura-2 ratio units) 
compared to 0.488 ± 0.056 fura-2 ratio units (paired t-te t ,  n = 1 1 cel ls)  in  the control 
experiments. 
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Figu re 1 8. Effects of  can nabid iol on am pl i tude and  t ime-cou rse o f  i n t race l lu lar  Ca2+ i n  rat 
ventricu lar  myocytes.(A) Typ ical  records of Ca2+ transients in an electrica l ly st imu lated ( 1  Hz) 
entricu lar myocytes superfused w ith either NT or NT + I flM C B D  and during  washout with 
T; scale bar i ndicates 0. 1 fura-2 rat io unit  (RU) .  A l so shown rest ing fura-2 rat io (340/380 nm)  
(B), t ime to  peak (TPK) ci+ t ransient (C), t ime to  ha l f  (THALF)  decay of the  Ca2+ transient ( D) 
and amp l itude of the Ca2+ transient (E) .  Myocytes were maintained at 3 5 -36  °c and superfused 
wi th  C B D  for 1 0  m inu tes. Data are shown as means ± SEM n= 1 1 - 1 4  cel l .  * ind icates stat i st ica l ly 
s ign i ficant d ifference at  the leve l of P< 0.05 .  
3.3 E ffect of a n n a b i d i o l o n  a rcopla m ic R e t ic u l u m  Ca2+ Tran port 
The dYect of BD n arc plasmic ret iculum a2+ transp rt wa te ted. 
F igure 1 9A h w a t)- pical record i l l ustrat ing the protocol used i n  the e experiments. 
59 
1 n i t ia l l  , the 111)- c te \ a e lectrical ly t imu lated at 1 Hz. Electrical st imulation was then 
turned off £i r 5 econds. affe ine \ as then app l ied for 1 0  seconds using a rapid sol ution-
exchanger device. � lectrical t imulat ion ',; as then restarted, and the recovery of 
i ntracel lular a2+ \ as recorded during a 60 seconds period. The SR Ca2+ content was 
a e sed by mea uring caffeine-evoked Ca2+ release (under the caffeine-evoked Ca2+ 
tran i ent) and fractional release of Ca2+ by comparing the ampl i tude of the e lectrical ly 
evoked steady-state Ca2 transients with that of the caffeine-e oked Ca2+ transient i n  the 
pre ence of e i ther T alone or T with 1 /-lM CBD.  Ma i mal ampl i tudes and the rates of 
Ca2+ re lea e by 20 mM caffeine remai ned unaltered after a 1 0  m inute bath appl ication of 
1 � l  1 CBD (F igure 1 9B )  and (F igure 1 9C;  paired I-test; n = 7 cel ls P>0.05 ) .  Fractional 
release of R Ca2+ was not s igni ficantly al tered in 1 /-lM CBD compared to NT (0 .78 ± 
0.04 i n  CBD versu 0 .8 1 ± 0.07 i n  controls;  pai red t-test ·  n =8 cel ls; F igure 1 9D).  The 
recovery of the CaH transients during e lectrical st imulat ion fol lowing app l ication of 
caffe ine ( Fi gure 1 9E )  was also not s ignificant ly  a l tered in myocytes exposed to 1 /-l M  
CBD myocytes compared t o  the control cel l s  (pa ired t-test; n = 8 ce l ls, P>0.05) .  
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Fig u re 1 9. E ffect of can nabidol  on sa rcoplasmic .·et icu l u m  Ca2+ t ransport. (A)  Typical  records 
i l l ustrating the experimental protocol . ( B) Comparison of the effect of caffeine app l i cation on the 
area under caffe ine-evoked Ca"+ transient i n  NT and C BD-treated ventricu lar myocytes. (C) 
Area under the curve. (D)Mean am p l itude of SR fract ional release of Ca2+ . ( E )  Recovery of 
e lectrica l l  evoked intrace l lu lar Ca2+ after appl icat ion of caffeine.  Data are mean ± S . E . M . , n = 7-
8 ce l l s .  
3.4 E ffect of  Ca n n a bid iol  on M ofi Ja mc n t  e n  i t iv i ty  to Ca2+ 
The effects of B D  n myofi lament en i t i  i t) to Ca2+ \.vere a lso investigated. 
6 1  
The e experiment te ted whether CBD decrea es the mechanical response by al tering 
the affi nity of the contracti le  machinery of the ventricular myocytes to intracel l ular Ca2+. 
typical record of myocyte hortening. fura-2 ratio and phase-plane diagrams of 
fura-2 rat io v er us ell length in  myocytes exposed to NT i shown in  Figure 20A. The 
gradi n1 f the trajector re flects the relative myofi lament response to Ca2+ and hence 
has been used as a measure of myofilament sensi t iv i ty to Ca2+( Spurgeon. et a I . ,  1 992; 
Howarth. t a l . .  2002) .  The gradients of the fura-2 -ce l l length trajectory during late 
rela,"ation of the twit h contraction mea ured during the periods 500-600 ms (F igure 
20B).  500-700 ms (F igure20C) ,  and 500-800 ms ( Figure20D) were not signi ficant ly  
altered in  CBD compared to  T suggesting that myofilament sensi t i  i ty to Ca2+ i s  not 
reduced by CBD (CB D-treatment was compared to NT containing 0.02 % D MSO, paired 
t-test: n = 1 7  c l I s '  P>0.05) .  
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Fig u re 20.  E ffect o f  can nabid iol o n  myofi lament  sensit ivity to Ca2+.(A) Typical record of 
myocyte shorten ing and fura-2 rat io and phase-plane d iagrams of fura-2 rat io vs. ce l l  length  in a 
myocyte exposed to T .  The arrow ind icates the region where the grad ient was measured. B-D 
shows the effects of I flM CBD on the mean gradient of the fura-2 ce l l  length  trajectory of the 
twi tch contract ion during the period 500-600 ( B) ,  500-700 (C) and 500-800 ms ( D )  of late 
re l�'(at ion. Data are mean ± S .E .M ., n = 1 7  ce l l s .  
3.5  Effect of  Ca n n a b i d i o l  o n  t h e  Act ion  Poten t i a l  of Ven tr icu la r  M yoc te  
In  th i  ' set of e. periment , patch-c lamped entricuJar m ocyte \ ere exposed to 
BD whi le c ntinuou J monit ring their re�1 and Ps in current clamp mode. The 
generation of P \va t imu lated by 0 .9- J nA depolarizing CUlTent pulses of 4 ms 
e the intracel Ju lar pipette o lution did not contain Ca2+-chelating agents, 
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the generat ion of each P was acc rnpanied by a myocyt contraction.  Therefore, CUlTent 
pul e were appl ied at a frequency of  0.2 Hz.  Dur ing a typical experiment the fol lowing 
protocol were employed : fi r t, whole-ce l l  configuration " as establ i shed and a 4 to 5 
mi nut d ia ly i of  the m 'ocytes with a pipette solut ion was al Jowed to ensure an 
equi l ibrium of condit ions between the pipette solution and the intracel lu lar mi l ieu .  A fter 
achieving stable recordi ngs of basel ine electrical act ivity (V resl and AP parameters), 
myoc te were expo ed to CBD for 5 to 1 0  minute and was subsequent ly washed out. 
The resting membrane potentia ls  (mean ± SEM) were -77.4 ± 1 .9 and -79.2 ± 1 . 7 
m V i n  the control and after CBD treatment (n=9) myocytes respectively (F igure 2 1  A, 
in  et and F igure 2 1 B) .  Maximal ampl i tudes of AP and the rising rate of AP (max imal 
elocity; Vis, F igure 2 I C  and Figure 2 1 D) were not s ignificantl y  altered in the presence 
of CBD.  CBD (1 J-lM) consistent ly  shortened the duration of AP ( measured at 60 % of 
repol arization, A PD60) (Figure 2 1 A  inset and Figure 2 1 E) .  Changes i n  AP shortening in  
response to CBD ( 1  J-lM) appl ications were noticeable within 20 to 30 seconds 
(F igure2 1 A). Recoveries were usual ly  part ial and required a longer t ime. 
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Figu re 2 1 .  E ffect of can n abid iol on the exci tabi l i ty of ventricu lar  myocytes. (A)  
Representative record ings show the APs in  controls (dark grey area), i n  the presence of 1 f.1M 
CBD ( l ight grey area) and after washout ( stri ped area) in a ventricu lar myocytes; the i nsets on 
pane l  A shO\\ the t ime course of act ion potent ia l  duration (APD60) and resting potent ia l  (Vrest) 
changes in  response to CBD app l ication ( i nd icated by horizontal bars). ( B-E)  show summary of 
C B D  effects on amp l itude and shape of the AP in  ventricu lar myocytes; quantification of the 
changes in Vrest{ B) AP ampl itude (C), AP maxima l  veloc i ty(D) and AP duration ( E ), 
characterized by APD60 i n  contro ls  (dark grey bars) and i n  response to 1 11M CBD ( l ight grey 
bars). Data are mean ± S .E .M . , n = 6 - 9 ce l l s  from 6 to 9 for each group .  
3.6 E ffect of a n n a b i d io l  on L-type Ca2+ C u rre n t  
e a l s  inve tigated the ffect of CBD ( 1  /lM )  o n  L-type Ca2+ cur ents. F igure 
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22A hov.. a t, pical record f L-type Ca2+ current ebcited b applying a single 300 ms 
vol tage pul e to + 1 0  mV from a holding potential of -50 mV in rat ventricular myocyte 
before and after a 1 0  minute uperfusion with 1 /l M  CBD.  The t ime frame of the effect of 
CBD on the density of L-t pe a2+ currents is shown in F igure 22B.  The appl ication of a 
vehic le  (0 .02% DM 0) for 1 0  minutes caused a 1 0- 1 5% i nhibit ion of the ClUTent density 
of L-type Ca2+ C LUTents in experiments l ast i ng up to 1 5  to 20 min. The effects of CBD 
'were also in e t igated on the bioph s ical propert ies of L-type Ca2+ currents in  rat 
\ entricular myocytes. L-t pe Ca2+ currents were recorded i n  the presence of intrace l lular 
+ and extrace l lu lar TEA + to suppress K+ currents whi l e  retain ing 95 mM Na + i n  the 
extracel lular solution. The e l imination of contaminating Na + cur ent dur ing the recordi ng 
of L-type Ca2+ currents was achieved by applying voltage step-pul ses from relatively 
depolarized Vh of -50 mY, which produced steady-state i nact ivation of sodium channels 
(Voitychuk, et a I . ,  20 1 2) .  As e ident from the original recordings and 1- V relationships 
(F igure23A), L-type Ca2+ currents started to appear at Vm = -30 mY, reached a 
maximum at around V m = + 1 0 m V,  and decreased at h igher voltages approaching to zero 
at about Vm = +60 mV ( Figure23 B ) . The maximal ampl i tudes of L-type Ca2+ cur ents 
were suppressed in the presence of CBD ( 1  /lM ) .  
3.6 Effect  of  C a n n a b i d io l  o n  L-ty pe Ca2+ C u rre n t  
We a ls  investigated the effect of CBO (1 J.!M) on L- t  pe Ca2+ cur ents. Figure 
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22A how a typical record of L-type Ca2+ c urrents e l ic i ted b applying a single 300 ms 
ol tage pul e to + 1 0 m V from a holding potent ial of -50 m V in  rat ventri cular myocyte 
before and after a 1 0  minute llperfusion with I J.!M CBO.  The t ime frame of the effect of 
CBO n the d nsi t  of L-type ci+ ClllTents is shown in Figure 22B.  The appl ication of a 
vehicl (0 .02% DM 0) for 1 0  minutes caused a 1 0- 1 5% inh ibit ion of the CUITent density 
of L-type Ca2+ currents in  experiments lasting up to 1 5  to 20 min .  The effects of CBO 
were a l  0 i nve tigated on the biophysical properties of L-type Ca2+ currents in rat 
\ entricular myoc tes. L-t pe Ca2+ cun"ents were recorded i n  the presence of i ntracel lular 
Cs + and extrace l lu lar TEA + to suppress K+ currents whi le retain ing 95 m M  Na + in the 
extracel lular o lut ion. The e l im ination of contami nat ing Na + current dming the recording 
of L-type Ca2+ CUlTents was achieved by applying voltage step-pUlses from rel at ively 
depolarized Vh of -50 mV which produced steady-state inactivation of sodium channels 
(Voi tychuk, et a1 . ,  20 1 2) .  As evident from the orig inal recordings and J- V relat ionships 
(F igme23A),  L-type Ca2+ currents started to appear at Vm = -30 mY, reached a 
max imum at around V m = + 1 0 m V,  and decreased at h igher voltages approaching to zero 
at about Vrn = +60 mV (F igme23B) .  The maximal ampl i tudes of L-type Ca2+ currents 
were suppressed in the presence of CBO ( 1  J.!M) .  
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Fiu u re 2 2. E ffect of can nabidiol on CaH currents  med iated b y  L-ty pe Ca2+ chan nels in  ra t 
vcn t ricular myocyte  . (A) CBD inh ib i t  L-type Ca2+ CU ITent recorded us ing \ hole-ce l l  vol tage­
c lamp mode of patch c lamp techn ique.  Current traces are recorded before (contro l )  and after 1 0  
m in  appl ication of 1 �M BD.  L-t) pe a2+currents were recorded during 300 ms oltage pu lses 
to + I 0 III from a hold ing pot nt ia l  of -50 mY.  (B )  Average of the maximal currents of YGCCs 
presented as a funct ion of t ime in  the presence of eh ic le (0.02% OM 0; fi l led c i rc les) and 1 �LM 
BD ( 11=5 ce l l ; open i rc les) .  Appl ication t ime for the agent was presented in  horizontal bar 
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Fig u re 23. The effect of can n a bid iol  on vol tage-c u rrent  characterist ics of L-type CaH 
chan nels i n  rat ven t ricu lar  myocytes.  (A)  Representative record ings of L-type Ca2+ currents in 
response to the depicted pu l se protocol under control condi t ions and after appl icat ion of 1 �M 
CBD. ( B) ormal i zed and a eraged J- V relat ionsh ips of control L-type Ca2+ currents(fi l led 
c i rc les) and L-type Ca2+ currents in the presence of 1 �M CBD (open c i rc les) determ i ned by 
apply ing  a series of step depolar iz ing pu lses from -70 mY to +70 mY in 1 0  mY i ncrements for a 
durat ion of 300ms. Data poin ts ( mean ± S .E .M . )  are from 5 to 7 ce l l s .  
C B O  did not change the tead - tate activation curve of the L-type ?+ a- current 
( 1 2 value in  (h control experi ment and in  the presence of CBD the are - 1 9 . 1  ± 0.4 
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m and - 1 7 .6  ± 0 .3 mY, re pecti e ly ;  n=6, Paired I-test, P>O.OS) (F igure 24 ). Howe er, 
there \\ a a h; perpo larizing shi ft  of L-type Ca2+ currents in tead -state inacti at ion by 
9.6 mV ( i .e . ,  [rom contro l  val ue Y I12= - 1 0 .2  ± 0.9 mY to V 112= - 1 9 . 8  ± 1 . 1  mY in the 
presence of C BD) ( Figure 24B).  However, there was l it t le effect on the slopes of the 
cun e (k = 7 .7  ± O .S  mY and k = -4.S ± 0.4 mY for the control activation and 
inactivat ion, r pectively, versus k = 7 .9  ± 0 .3  mY and k = -4 .2  ± 0 .3 mV for the CBD-
modi fied act i ation and i nactivat ion, correspondingly) .  
In l ine with earl ier reports ( So ldatov, et a I . ,  1 998), k inetic analysis of L-type 
Ca2+ current were t i t led to a double-exponential function with fast (Tr) and slow (15 )  
inact ivat ion t ime constants. Compari son of L-type ci+ currents i n  the absence and 
pre ence of CBD revealed noticeable acceleration of the current's inactivation kinetics by 
CBD.  Quant ification of the t ime constants of L-type Ca2+ currents inact ivat ion showed 
that CBD ( 1  /-lM) significantly reduced 1j in the range of Vm -30 mV and + 1 0  mY (F igure 
2S) .  
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Figu re 24. E ffect o f  can nabid iol on steady state activation a n d  i n activation o fL-type Ca2+ 
cu rrent in rat ventricu la r  myocytes. Steady-state act ivation (A) steady-state i nact ivation (SS I )  
( B) curve of L-type Ca2+ currents i n  t he  absence (fi l led c i rc les) and presence of  1 11M CBD 
(open c i rc les). Data are mean ± S .E .M,  11= 5 ce l l s  are from 5 cel ls. F i t  of  experimental data points 
with Bol tzmann equat ion. 
69 
� 300 !� () (J) 
� 
s 
Q 
!- -,�, ..,. 
! � 200 '--" �O-Q � 
� -----0 Q ro � 
C/J 
� 1 00 0 
() 
(J) t t- -t �--t 8 . �  � 0 
-20 - 1 0 0 1 0 20 
voltage (m V) 
Figu re25. E ffect of can nabidiol  o n  t h e  ki netics ofL-type Ca2+cu lTents i n  rat ven t ricu lar  
myocytes. Voltage-dependent fast (triangles) and slow (c irc les) i nact ivation t ime constants (l i )  of 
L -type Ca2+ currents under control cond i t ions ( fi l led c irc les, and triangles) and in the presence of 
1 � CBD (open c i rc les and triangles). Data are mean ± S .E .M .  n= 5 -6 cel ls .  
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C h a pter  4: D i  e ll ion 
Our results sho\ that CBD ha a negat ive inotropic effect on the contracti l i ty of rat 
ventricular m 'ocyte . The negat ive inotropic effect of CBD appears to be mainly due to 
impaired a:! signa l ing in cardiomyocytes. Furthermore, the results indicate that the 
impaired a2+ ignal ing emanate from the inhibitory effects of CBD on the function of L 
t) pe a2+ hannel .  
A tion f BD on the cardiovascular system in fl uences mUlt iple organ systems 
and i l1\ Iv  comple ' cel lu lar and molecular mechanisms ( see Baranowska-Kuczko, 
Maclean, K zl , ka and Mal inowska, 20 1 2; tanley et a l . ,  20 1 3 ) . CBD has been shown 
to bave varioL! effect on muscular structures, neuronal and endothel ial  ce l l s  and alter the 
act ivit ies of everal receptors and ion channels d i rectly ( see Hejazi et aI . ,  2006; Pert wee 
_008� _0 1 0).  FurthemlOre. other factors such as the activat ion of autonomic reflexes, the 
pre en e of endothel ial  ce l ls  and fatty-ac id  based metabol ic  products have been reported 
to contribute to the complexity of CBD actions on the heart ( Pertwee 2008; Stanley et a I . ,  
20 1 3 ) .  On the other hand, acutel y  d issociated ventricular myocytes have several 
advantage over in-vivo and tradit ional in-vitro conditions, since it excludes some of the 
factors mentioned above and also the influences of reflex pathways, autonomic nerve 
endings, neurotransmitter uptake systems, gap-j unction connections and coronary 
perfusion status.  
In our experiments, using video edge detect ion techniques i n  individual myocytes, 
it was found that C B D  causes a sign ificant reduction in the max imal ampl i tude of 
shortening (expressed as a percentage of resting ce l l  length) without a l tering the t ime 
frame ( such as TPK shortening and THALF rel axation) of myocytes shortening. Our 
7 1  
fi ndi ng from m 'oc te shortening and intracel l ular 2+ . .  a mea urement expenments are 1 11 
agreement with earl ier tudies report ing that CBD exerts a negative-inotropic effect i n  
isolated-cardiac muscle  preparat ions ( Smi le . Karler and Turkanis ,  1 976; ahas and 
Trouve, 1 985) .  Furthermore, re ults from our study suggest that a d i rect i nteraction of 
CBD \,vlth ventricular myocytes, rather than the actions of CBD on nerve endings and 
neurotran mi tter uptake stems are main ly responsible for the negat ive inotropic effects 
of CBD in the herui. 
The negat ive-inotropic actions of CBD m ight be attributed to the impaired release 
of Ca2+ from the R. In fact, CBD and other cannabinoids have been reported to 
modulate the ryanodine sensitive intrace l l ular Ca2+ stores in neurons ( Drsydale et a I . ,  
2008) gl ia ( Mato e t  aI . ,  20 1 0 ;  Pertwee et a I . ,  20 1 0) .  However, the  ampl i tude and k inetics 
of  caffe ine-induced Ca2+ relea e from i ntracel l ular Ca2+ stores were not changed by CBD 
suggest ing that ryanodine-sensit i  e intracel lu lar Ca2+ stores ru·e not involved i n  the 
negative- inotropic effects of  CBD observed in thi s  study. 
Cannabidio l  can al ter the level s  of  second messengers such as cAMP, cGMP and 
protei n  k inase C which are known to be involved in tuning the Ca2+ sensitivity of the 
contracti le proteins.  I n  an earl ier study of cardiac muscle membranes, cAMP level s  have 
been shown to be unaltered in the presence of C B D  ( H i l lard, Pounds, Boyer and B loom, 
1 990), Furthermore, the sensi t iv i ty of contract i le  proteins to i ntrace l lular Ca2+ remained 
unchanged in the presence of CBD suggesting that phosphorylation and de-
phosphoryl ation of the contracti le proteins did not p lay a significant role in the negat ive-
i notropic action of CBD.  Col lectively, these resul ts suggest that the effects of CBD on 
myocyte contracti l i ty are not related to changes in i ntrace l lu lar Ca2+ release machinery or 
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ensit ivit} of my fi lament to Ca2+. I n  addit ion, in the pre ence of BD, resting Ie  els of 
intrace l lular a2+, and cell length of entricular myocyte , remained unalt ered suggesting 
that CBD do not igni ficant ly  affect Ca2+ homeostasi under rest ing cond itions. 
During e. citation-contract ion coupl ing, alterat ion in the ampl i tudes and kinetics 
of the card iac action potential ( P) are c losel a soc iated with corresponding chan ges in 
the contracti l ity of myocyte . I n  our stud , cardiac APs were recorded using the whole  
cel l patch c lamp technique. I t  was found that the ampl i tudes and dV/dtma, of APs were 
not al tered in the presenc of CBD suggesting that ol tage-gated sodium channels are not 
affected by CBD. For thi reason, the effect of CBD on the functional propert ies of 
\ol tage-gated sodium chan nels  was not i nvestigated any further. However, the decrease 
of AP durat ion, and suppression of the second phase of the AP was evident in \ hole cel l 
recordi ngs from cardiomyocytes. ince the plateau (phase 2) of AP is  mainly due the 
influx of Ca2+ through L-type voltage-gated Ca2+ chalmels, these results suggest that 
CBD can act on L-type Ca2+ channels .  I ndeed, whole cel l recordings of Ca2+ currents in  
cardiomyocytes, i n  agreement with the recordings of A Ps, i ndicated that CBD inhibi ts 
potent ly the function of L-type voltage-gated Ca2+ channel s  with an ICso value of 0 .6 /-lM.  
An analysis of current k inetics indicated that the i nact ivation of  Ca2+ currents can double 
the exponentia l  decay and CBD can decrease the ampl i tudes of the Ca2+ currents by 
accelerat ing both fast and slow components of the inactivation process. The effects of 
CBD on the gati ng characterist ics of Ca2+ channels were further i nvestigated by studying 
the act ivation and i nactivation curves i n  the absence and presence CBD.  A lthough half 
activation voltage and the s lope of the activation curve were not al tered, there was a 
h) perpolarizing- h i ft of the inacti at ion curve further suggesting that CBD changes the 
voltage-d pendent inacti at ion process. 
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ol lecti ely, the e resul ts uggest that during exci tation-contraction coupl ing, 
shorten ing of action potential due to the i nh ibition of L-type Ca2+ channels decreases 
Ca2+- induced Ca2+ release from R and causes the negative-inotropic effect of CBD 
observed in  our  experiments and reported in  earl ier studies. In l i ne with these findings, 
al though caffe ine i nduced contractures and myo fi lament sensit ivi ty to Ca2+ remained 
unchanged. electrical ly-induced Ca2+ transients were significantly  depressed by CBD;  
further sugge t ing that Ca2+- induced Ca2+ release was impaired in  the presence of CBD.  
I n  earl ier studies CBD has been reported to  i nhibit the  uptake of dopami ne and other 
neurotransmitters ( Poddar and Dewey, 1 980; Pandol fo,  et a I . ,  20 1 1 ) . However, an uptake 
mechanism i s  not I i kel  to be i nvolved in  our studies on isolated ventricular myocytes. 
Furthermore, i nh ibit ion of uptake mechanisms for dopami ne and/or catecholamines such 
as epinephrine and norepinephrine wou ld  lead to wel l -establ i shed posit ive inotropic 
actions. rather than a negative i notropic effect as observed in the present study.  
Although CBD does not activate known cannabinoid receptors, some of its 
pharmacological actions have been shown to be reversed by cannabinoid receptor 
antagon ists (Pertwee, 2008). Recent studies have shown that the antagonist sensit ivi ty of 
CBD effects i s  due to the inhib i tion of fatty  acid  amide hydrolase act ivi ty an enzyme that 
i nactivates endogenous cannabinoids and related to subsequent increases in t i ssue 
endocannabinoids levels ( Pertwee, 20 1 0). However both ampl itudes of myocyte 
shortening and the L-type Ca2+ currents were not a ltered by U RB597, a potent inhibitor 
f fau) ac id amid hydrolase ( I Kury et a1 . 20 1 4 ).  suggesting that the acti ity of 
increased fatt) acid amide hydroJa e wa not involved in the act ions ob erved in CBD.  
fhe interact ion bet',: een L-type a2+ channels  and BD ha not been studied in  
deta i l .  In  an earl ier tud . 4 5  a2+-uptake in  brain s naptosomes had been shown to be 
inhibited by BD ( I larri and tokes. 1 982) .  imi larly. CBD induced increases in  
intracel l u lar a2+ J e  el w r found to be sensi t ive to blockers of L-type Ca2+ channels 
( Dr} dalc et a1 . .  2006). In agreement with these re u l ts, contractions of smooth muscles 
e l ic i ted b ' high-K+-containing solutions were also sign i ficantly inhibi ted by CBD 
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( l uny, a) lor. Whitt le and Javid, 20 1 1 ) . The interaction between T-type Ca2+ channe ls  
and BD was invest igated in  a recent stud , on human Ca V3 channels stably expressed 
in human embryonic k idney 293 ce l l s  and T-type channels in mouse sensory neurons 
( Ros et a I . ,  2008). At moderately h perpolarized potentials, CBD inhibi ted peak Ca V 3 . l 
and CaV3 .2  currents with ICso values of 1 J..lM but was less potent on CaV3 .3  channels .  
CBD inhibited sensory neuron T-type channels  by about 45% at 1 J..lM .  However, in  
recordings made from a holding potential of  -70 mY, 1 00 n M  CBD inhibited more than 
50% of the peak Ca V3 . 1  cur ent. CBD produced a signi ficant hyperpolarizing shift i n  the 
steady state i nactivation potentials for each of the Ca V3 chmmel s  ( Ross et a I . ,  2008). I n  
this respect our results indicate for the first t ime that C B D  i nhibits the function o f  L -type 
Ca2• channel s  in ventricular myocytes. 
In c l in ical studies, i t  has been shown that acute CBD i ntake does not cause a 
significant change i n  b lood pressure and heart rate ( S  tmlley, 20 1 3a) . However, several 
earl ier studies i ndicate that i ncreases in blood pressure and heart rate during stressful 
condi t ions are markedly  attenuated by CBD (Gomes, et a I . ,  20 1 3 ;  Granjeiro, Gomes, 
U1marae , orrea and Re tel , 20 J 1 :  Resste l ,  Joca, Moreira, Correa and Guimarae , 
2006: RcssteL et a I . ,  2009). I n  fact, in in vivo studies, it has been demonstrated that 
in rea ed heart rate and bl od pressure, one of the most consistent effects of call11abis 
intoxicati n, are signi ficantly decrea ed b CBD ( ahas and Trouve, 1 985) .  These 
tud ie ugge t that CBD can exert negat ive inotropic and chronotropic actions under 
certain c l in ical cond it ions such as stress and cal1J1abi s intoxication. 
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BD, in  the concentration range used in this study (0 . 1 - 1 0 �M), has been shown 
to modulate function of various receptors and ion channels such as Ca::!+ channels ( Ross 
et a I . ,  2008 ) .  5-HT3 ( Yang et a1 . ,  20 1 0 ), and nicot in ic  receptors ( Mahgoub et a I . ,  20 1 3 ) .  
Th peak pIa ma concentrat ions of CBD in healthy vol unteers fol lowing administration 
of ativex lM ( 1 : 1 ratio of 9-THC and CBD) was reported to be between O.O l �M to 
0 .05�l M  ( Mas i, et aI . ,  20 1 3 ) .  In earl ier c l in ical studies, mean CBD levels of 0.036 �M 
were determined in  blood analysis fol lowing a 6-\ eek oral treatment with CBD at doses 
of 1 0  mg/kg/day (Consroe et a I . ,  1 99 1 ). However, CBD is a highly l ipophi l ic  compound 
and eas i ly  passes biological membranes and accumulates in  t issues and i t  can reach to 
several fold higher t issue concentrations than i n  blood . Col lectively, these findings 
suggest that C BD, at relatively high concentrations, can suppress the funct ion of the 
cardiovascu lar system. In fact, cardiac fai l ure due to depressed heart contract i l i ty has 
been suggested to be the main cause of mortal i ty t hrough cannabis i ntoxication 
( Bergamasch i  et a I . ,  20 1 1 ) . Thus it is l i ke ly  that some of the effects of the cal1J1abis  plant 
are mediated by CBD during cal1J1abis i ntoxication. 
In  addi tion to card iac contract i l i ty .  the l ectrical act iv ity of heart ha al 0 been 
suggested t be affected b BD.  I n  an earl ier tudy, CBD has been shown to have 
beneficial action in  i chemia-i nduced card iac arrhythmias ( Walsh et a I . ,  20 1 0) .  The 
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horten ing of the AP duration by CBD observed in our study can be beneficial or 
harmfu l .  depending on the und rlying pathology. Thus, during acute ischemia, in which 
the durat ion f the cardiac PD i already shortened, a further decrease should be 
proanhythmic ( Den Ruij ter et a1 . .  2007). However, shortening of AP durat ion should be 
beneficial  i n  pr vent ing those arrhythmia caused by triggered activities observed in  
conditions such a heart fai l ure ( Den Ruij ter e t  a I . ,  2007). I n  conc lusion, the results 
indicate for the fi rst t ime, that CBO i nh ibits myocyte contracti l i ty by act ing on L-type 
Ca2+ channel . 
7 7  
C h a p t e r  5 :  L i m i ta t i o n  a n d  F u t u re D i rect i o ns 
The cope of thi re earch i mainly concemed with the effect of CBD on healthy 
ventricular cel ls ,  although end cannabinoids are tr s i nduced neurotransmitters. I n  
addit i  n t o  the effl cts f BD on L- type calcium channel i t  effect on CX should also 
be e tabl i  hed due to th ir i n fl uence on cytosol ic  calcium level and the viabi l i ty of 
ventricular cel l s  in  the pre ence of CBD. 
Future re earch may also include expressing calc ium channels  onto H EK-293 cel l s, 
thi a l lO\\'s u to exclude or incl ude the ind i rect effects of C B D  on intrace l lu lar signal ing 
that can affect calcium channel . nother method is to express the calcium channel each 
ubun it at a t ime and find where CBD exerts it effects most effectively and thereby 
estab l i  h the mechan ism by \ bich CBD exerts there effects. 
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